1
|
Bechmann L, Bauer K, Zerban P, Esser T, Tersteegen A, Fuchs SA, Kaasch AJ, Wolleschak D, Schalk E, Fischer T, Mougiakakos D, Geginat G. Prevention of legionella infections from toilet flushing cisterns. J Hosp Infect 2024; 146:37-43. [PMID: 38224856 DOI: 10.1016/j.jhin.2023.12.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 11/27/2023] [Accepted: 12/10/2023] [Indexed: 01/17/2024]
Abstract
INTRODUCTION Immunocompromised patients are at an increased risk of severe legionella infections. We present the results of an outbreak investigation initiated following a fatal case of hospital-acquired legionellosis linked to contaminated water from a toilet-flushing cistern. Additionally, we provide experimental data on the growth of Legionella spp. in flushing cisterns and propose a straightforward protocol for prevention. METHODS We monitored the growth of Legionella spp. in the building's hot- and cold-water systems using quantitative bacterial culture on selective agar. Molecular typing of Legionella pneumophila isolates from the infected patient and the water system was conducted through core-genome multi-locus sequence typing (cgMLST). RESULTS Legionella contamination in the hospital building's cold-water system was significantly higher than in the hot-water system and significantly higher in toilet flushing cistern's water compared with cold water from bathroom sinks and showers. Isolates from the patient and from the flushing cistern of the patient's bathroom were identical by cgMLST. In an experimental setting, daily toilet flushing for a period of 21 days resulted in a 67% reduction in the growth of Legionella spp. in the water of toilet flushing cisterns. Moreover, a one-time disinfection of cisterns with peracetic acid, followed by daily flushing, decreased legionella growth to less than 1% over a period of at least seven weeks in these setting. CONCLUSIONS One-time disinfection of highly contaminated cisterns with peracetic acid and daily toilet flushing as short-term measure can significantly reduce legionella contamination in flushing cisterns. These measures may aid in preventing legionella infection among immunocompromised patients.
Collapse
Affiliation(s)
- L Bechmann
- Department of Medical Microbiology and Infection Control, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
| | - K Bauer
- Department of Medical Microbiology and Infection Control, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - P Zerban
- Department of Medical Microbiology and Infection Control, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - T Esser
- Department of Medical Microbiology and Infection Control, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - A Tersteegen
- Department of Medical Microbiology and Infection Control, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - S A Fuchs
- Institute of Medical Microbiology and Hospital Hygiene, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
| | - A J Kaasch
- Department of Medical Microbiology and Infection Control, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - D Wolleschak
- Department of Haematology and Oncology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - E Schalk
- Department of Haematology and Oncology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - T Fischer
- Department of Haematology and Oncology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - D Mougiakakos
- Department of Haematology and Oncology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| | - G Geginat
- Department of Medical Microbiology and Infection Control, Otto-von-Guericke University Magdeburg, Magdeburg, Germany
| |
Collapse
|
2
|
Whynot D, Fischer T, Keniston A, Lewandowski A, Briggs K. A - 75 Neuropsychological Consequences of Anoxic Encephalopathy Pursuant to Myocardial Infarction. Arch Clin Neuropsychol 2023; 38:1238. [PMID: 37807191 DOI: 10.1093/arclin/acad067.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/10/2023] Open
Abstract
OBJECTIVE Myocardial infarctions (MI) often result in irreversible muscle damage to the heart and difficulty returning to daily activities. While the physical consequences of acute cardiac events are well documented in the medical literature (Lesperance et al., 1996), there is less research identifying the cognitive, emotional, and behavioral consequences of MI (Brink et al., 2008) particularly when complicated by anoxia and unresponsiveness. METHOD We present a case study of a 54-year-old right-handed male with 12 years of education referred for neuropsychological assessment pursuant to mental status changes following a MI with an estimated 25-30 minutes of unresponsiveness and subsequent diagnosis of anoxic encephalopathy, supported by neuroimaging, which is also positive for a 4 mm pituitary tumor. RESULTS Neuropsychological assessment revealed difficulties with cognitive efficiency, sequencing, language production, phonemic fluency, and memory. Performance was also inconsistent with age- and education-weighted norms, and therefore did not reflect a normal aging profile. An objective psychological inventory (PAI) revealed negative self-evaluation, a focus on health matters, acute stress, and substance concerns. Additionally, an endorsement of social isolation, discomfort in social interactions, and a readiness to express anger verbally was indicated. Findings supported diagnosis of cognitive impairment associated with anoxic brain injury from above noted MI. CONCLUSION This case provides an example of the neuropsychological consequences of anoxic encephalopathy from MI on cognitive, emotional and behavioral functioning. It also supports the need for awareness of bodily health within the context of overall cognitive health. It emphasizes the benefits of integrating physiological and neurocognitive symptoms when conceptualizing patients with cardiac arrest.
Collapse
|
3
|
Horeman-Franse T, Postema RR, Fischer T, Calleja-Agius J, Camenzuli C, Alvino L, Hardon SF, Bonjer HJ. The relevance of reducing Veress needle overshooting. Sci Rep 2023; 13:17471. [PMID: 37838824 PMCID: PMC10576755 DOI: 10.1038/s41598-023-44890-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 10/13/2023] [Indexed: 10/16/2023] Open
Abstract
Safe insertion of the Veress needle during laparoscopy relies on the surgeons' technical skills in order to stop needle insertion just in time to prevent overshooting in the underlying organs. To reduce this risk, a wide variety of Veress needle systems were developed with safety mechanisms that limit the insertion speed, insertion depth or decouple the driving force generated by the surgeon's hand on the needle. The aim of this study is to evaluate current surgeons' perceptions related to the use of Veress needles and to investigate the relevance of preventing overshooting of Veress needles among members of the European Association of Endoscopic Surgery (EAES). An online survey was distributed by the EAES Executive Office to all active members. The survey consisted of demographic data and 14 questions regarding the use of the Veress needle, the training conducted prior to usage, and the need for any improvement. A total of 365 members residing in 58 different countries responded the survey. Of the responding surgeons, 36% prefer the open method for patients with normal body mass index (BMI), and 22% for patients with high BMI. Of the surgeons using Veress needle, 68% indicated that the reduction of overshoot is beneficial in normal BMI patients, whereas 78% indicated that this is beneficial in high BMI patients. On average, the members using the Veress needle had used it for 1448 (SD 3031) times and felt comfortable on using it after 22,9 (SD 78,9) times. The average years of experience was 17,6 (SD 11,1) and the surgeons think that a maximum overshoot of 9.4 (SD 5.5) mm is acceptable before they can safely use the Veress needle. This survey indicates that despite the risks, Veress needles are still being used by the majority of the laparoscopic surgeons who responded. In addition, the surgeons responded that they were interested in using a Veress needle with an extra safety mechanism if it limits the risk of overshooting into the underlying structures.
Collapse
Affiliation(s)
- T Horeman-Franse
- Department of Biomechanical Engineering, Delft University of Technology, TU-Delft, Mekelweg 2, 2628CD, Delft, The Netherlands.
- European Association of Endoscopic Surgery, Eindhoven, The Netherlands.
| | - R R Postema
- Department of Biomechanical Engineering, Delft University of Technology, TU-Delft, Mekelweg 2, 2628CD, Delft, The Netherlands
- Department of Surgery, Amsterdam University Medical Centers, Location VUMC, Amsterdam, The Netherlands
| | - T Fischer
- Department of Biomechanical Engineering, Delft University of Technology, TU-Delft, Mekelweg 2, 2628CD, Delft, The Netherlands
| | - J Calleja-Agius
- Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
| | - C Camenzuli
- Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta
| | - L Alvino
- Neyenrode Business School, Amsterdam, The Netherlands
| | - S F Hardon
- Department of Biomechanical Engineering, Delft University of Technology, TU-Delft, Mekelweg 2, 2628CD, Delft, The Netherlands
- Department of Surgery, Amsterdam University Medical Centers, Location VUMC, Amsterdam, The Netherlands
| | - H J Bonjer
- Department of Surgery, Amsterdam University Medical Centers, Location VUMC, Amsterdam, The Netherlands
- European Association of Endoscopic Surgery, Eindhoven, The Netherlands
| |
Collapse
|
4
|
Zahn R, Schmidt M, Wallner A, Fischer T, Ohlendorf D, Wanke EM. Work-Related Dermatoses of the Feet in Professional Dancers: A Pilot Study. Med Probl Perform Art 2023; 38:16-22. [PMID: 36854972 DOI: 10.21091/mppa.2023.1003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 10/11/2022] [Indexed: 06/18/2023]
Abstract
OBJECTIVE The feet of professional dancers are exposed to high work-related stresses. To date, data from the professional dance sector concerning this matter are lacking. The aim of this exploratory project was to analyze and evaluate skin health in the foot area with regard to the prevalence of dermatoses, their locations, as well as gender-specific and load-specific differences. METHODS Professional classical and neo-classical ballet dancers were examined at two time points: in a phase with increased stress (T0: daily training sessions, rehearsals, and high performance frequency) (n=51, 35 females, 16 males) and after a 24-day rest phase (T1: n=35, 28 females, 7 males). In addition, gender-specific and load-specific (T0 and T1) differences were evaluated. RESULTS All professional dancers were affected by skin lesions of the feet at T0. Hyperkeratosis (96.1%), onychomycosis (27.5%), and subungual hematoma (11.8%) were the most frequent dermatoses of the feet of professional dancers. Onychomycosis affected the nails of the big toes in particular (right 15.7%; left 13.7%), and subungual hematomas were found exclusively on the nails of the first toe (right 7.8%; left 7.8%). Women tended to be more frequently affected by hyperkeratosis, men more frequently by onychomycosis. There were no load-specific differences between the stress and rest phases. CONCLUSION The prevalence of work-related dermatoses is equally high among female and male dancers. The results can be used for further research and serve as a basis for specific measures of behavioral and environmental prevention in dance.
Collapse
Affiliation(s)
| | | | | | | | | | - E M Wanke
- Institute for Occupational, Social and Environmental Medicine, Johann Wolfgang Goethe University Frankfurt am Main, Theodor-Stern-Kai 7, Haus 9, 60590 Frankfurt am Main, Germany. Tel 00496963016650.
| |
Collapse
|
5
|
Keller J, Stern S, Chang SC, Marcus R, Weiss J, Nassoiy S, Christopher W, Fischer T, Essner R. Correction: Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound. Ann Surg Oncol 2023; 30:3656-3657. [PMID: 36807024 DOI: 10.1245/s10434-023-13186-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Affiliation(s)
- Jennifer Keller
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Stacey Stern
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | | | - Rebecca Marcus
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Jessica Weiss
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Sean Nassoiy
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | | | - Trevan Fischer
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Richard Essner
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA.
| |
Collapse
|
6
|
Nassoiy S, Christopher W, Marcus R, Keller J, Weiss J, Chang SC, Essner R, Foshag L, Fischer T, Goldfarb M. Evolving management of early stage pancreatic adenocarcinoma in older patients. Am J Surg 2023; 225:212-219. [PMID: 36058752 DOI: 10.1016/j.amjsurg.2022.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 07/25/2022] [Accepted: 07/28/2022] [Indexed: 12/30/2022]
Abstract
BACKGROUND Due to the aging population, the number of older patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) will continue to rise. STUDY DESIGN Utilizing the NCDB from 2010 to 2016, patients with early stage, clinically node negative PDAC who were ≥70 years old and had a Whipple were identified. Multivariable logistic regressions were used to determine independent factors for R0 resection and NAT. Cox-proportional-hazards regression analyses examined for the impact of NAT on the risk of death. RESULTS Of 5086 patients, 51.7% received upfront surgery + adjuvant therapy (UFS + AT), followed by 29.9% UFS only, and the remainder NAT. NAT significantly improved OS compared to a combined cohort of those that had UFS ± AT. NAT retained its independent survival benefit when compared to only patients that had UFS + AT. CONCLUSION For older patients diagnosed with early stage PDAC, NAT was associated with improved R0 resection rates and a significant survival benefit when compared to the current standard of care.
Collapse
Affiliation(s)
- Sean Nassoiy
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | | | - Rebecca Marcus
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | - Jennifer Keller
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | - Jessica Weiss
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | | | - Richard Essner
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | - Leland Foshag
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | - Trevan Fischer
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | | |
Collapse
|
7
|
Keller J, Stern S, Chang SC, Marcus R, Weiss J, Nassoiy S, Christopher W, Fischer T, Essner R. ASO Visual Abstract: Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound. Ann Surg Oncol 2022; 29:8478-8479. [PMID: 36059034 DOI: 10.1245/s10434-022-12402-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
- Jennifer Keller
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Stacey Stern
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | | | - Rebecca Marcus
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Jessica Weiss
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Sean Nassoiy
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | | | - Trevan Fischer
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Richard Essner
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA.
| |
Collapse
|
8
|
Keller J, Stern S, Chang SC, Marcus R, Weiss J, Nassoiy S, Christopher W, Fischer T, Essner R. Predicting Regional Lymph Node Recurrence in the Modern Age of Tumor-Positive Sentinel Node Melanoma: The Role of the First Postoperative Ultrasound. Ann Surg Oncol 2022; 29:8469-8477. [PMID: 35989390 DOI: 10.1245/s10434-022-12345-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 07/18/2022] [Indexed: 11/18/2022]
Abstract
BACKGROUND The Multicenter Selective Lymphadenectomy Trial II (MSLT-II) led to a change in the management of tumor-positive sentinel lymph nodes (SLNs) from completion node dissection (CLND) to nodal observation. This study aimed to evaluate prognostic factors for predicting sentinel node basin recurrence (SNBR) using data from MSLT-II trial participants. METHODS In MSLT-II, 1076 patients were treated with observation. Patients were included in the current study if they had undergone a post-sentinel node basin ultrasound (PSNB-US) within 4 months after surgery. The study excluded patients with positive SLN by reverse transcription-polymerase chain reaction (RT-PCR) or incomplete SLN pathologic data. Primary tumor, patient, PSNB-US, and SLN characteristics were evaluated. Multivariable regression analyses were performed to determine independent prognostic factors associated with SNBR. RESULTS The study enrolled 737 patients: 193 (26.2%) patients with SNBR and 73 (9.9%) patients with first abnormal US. The patients with an abnormal first US were more likely to experience SNBR (23.8 vs. 5.0%). In the multivariable analyses, increased risk of SNBR was associated with male gender (adjusted hazard ratio [aHR], 1.38; 95% confidence interval [CI], 1.00-1.9; p = 0.049), increasing Breslow thickness (aHR, 1.10; 95% CI, 1.01-1.2; p = 0.038), presence of ulceration (aHR, 1.93; 95% CI, 1.42-2.6; p < 0.001), sentinel node tumor burden greater than 1 mm (aHR, 1.91; 95% CI, 1.10-3.3; p = 0.022), lymphovascular invasion (aHR, 1.53; 95% CI, 1.00-2.3; p = 0.048), and presence of abnormal PSNB-US (aHR, 4.29; 95% CI, 3.02-6.1; p < 0.001). CONCLUSIONS The first postoperative US together with clinical and pathologic factors may play an important role in predicting SNBR.
Collapse
Affiliation(s)
- Jennifer Keller
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Stacey Stern
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | | | - Rebecca Marcus
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Jessica Weiss
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Sean Nassoiy
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | | | - Trevan Fischer
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA
| | - Richard Essner
- Providence Saint John's Cancer Institute, Santa Monica, CA, USA.
| |
Collapse
|
9
|
Nassoiy S, Christopher W, Marcus R, Keller J, Weiss J, Chang SC, Foshag L, Essner R, Fischer T, Goldfarb M. Treatment Utilization and Outcomes for Locally Advanced Rectal Cancer in Older Patients. JAMA Surg 2022; 157:e224456. [PMID: 36169964 PMCID: PMC9520439 DOI: 10.1001/jamasurg.2022.4456] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 06/18/2022] [Indexed: 12/14/2022]
Abstract
Importance The number of older patients (80 years and older) diagnosed with locally advanced rectal cancer (LARC) is expected to increase. Although current guidelines recommend neoadjuvant chemoradiation therapy (NACRT) followed by resection, little is known about management and outcomes in this older population. Objective To assess the trends in management of older patients diagnosed with LARC who had a surgical resection. Design, Setting, and Participants Patients 80 years and older who had a surgical resection for LARC were identified in the 2004-2016 National Cancer Database. Patients were grouped based on therapy sequence: (1) surgery followed by adjuvant therapy (AT), ie, chemotherapy or radiation; (2) surgery alone; or (3) NACRT followed by surgical resection. Data were analyzed in May 2021. Exposures NACRT followed by surgery, and surgery with or without AT. Main Outcomes and Measures Overall survival (OS) was assessed using Kaplan-Meier analyses with inverse probability of treatment weighting (IPTW) and Cox proportional hazards regression were performed to examine the association of NACRT with the risk of death. Results Of 3868 patients with LARC who underwent surgical resection, 2042 (52.8%) were male, and the mean (SD) age was 83.4 (3.0) years. A total of 2273 (58.8%) received NACRT followed by surgical resection. Factors independently associated with NACRT were more recent diagnosis, age 80 to 85 years (vs 86 years and older), fewer comorbidities, larger tumors, and node-positive disease. The Kaplan-Meier analyses with IPTW showed that 3-year and 5-year OS for NACRT (3-year: 68.9%; 95% CI, 67.0-70.8; 5-year: 51.1%; 95% CI, 49.0-53.4) vs surgery with AT (3-year: 64.4%; 95% CI, 59.0-70.2; 5-year: 43.0%; 95% CI, 37.4-49.5) vs surgery alone (3-year: 55.8%; 95% CI, 52.0-60.0; 5-year: 34.7%; 95% CI, 30.8-39.0) was significantly different (P < .001). After adjusting for confounders, patients who received NACRT were more likely to undergo an R0 resection (adjusted odds ratio, 2.16; 95% CI, 1.62-2.88), which independently improved OS (P < .001). Moreover, receipt of NACRT was independently associated with a 25% decreased risk of death (adjusted hazard ratio, 0.75; 95% CI, 0.69-0.82) compared with alternative treatment sequences. Conclusions and Relevance Approximately 40% of older patients with LARC did not receive the current standard of care. In this cohort, NACRT was associated with a higher likelihood of an R0 resection and improved OS. Clinicians should advocate for receipt of NACRT in older patients with LARC.
Collapse
Affiliation(s)
- Sean Nassoiy
- Providence St John’s Cancer Institute, Santa Monica, California
| | | | - Rebecca Marcus
- Providence St John’s Cancer Institute, Santa Monica, California
| | - Jennifer Keller
- Providence St John’s Cancer Institute, Santa Monica, California
| | - Jessica Weiss
- Providence St John’s Cancer Institute, Santa Monica, California
| | | | - Leland Foshag
- Providence St John’s Cancer Institute, Santa Monica, California
| | - Richard Essner
- Providence St John’s Cancer Institute, Santa Monica, California
| | - Trevan Fischer
- Providence St John’s Cancer Institute, Santa Monica, California
| | | |
Collapse
|
10
|
Huttelmaier M, Muensterer S, Morbach C, Sahiti F, Scholz N, Albert J, Angermann C, Ertl G, Frantz S, Stoerk S, Fischer T. Mortality risk is increased in chronotropic incompetent device carriers with acute heart failure. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
In heart failure (HF), chronotropic incompetence is a major factor limiting cardiac output and exercise capacity. In patients carrying cardiac implantable electronic devices (CIED), accelerometer-based rate adaption (R-mode) counterbalances chronotropic incompetence during physical activity but fails to modulate heart rate under circumstances of high metabolic demand.
Purpose
We hypothesized that an activated R-mode, a surrogate of chronotropic incompetence, indicates worse prognosis during and after episodes of acutely decompensated HF (AHF).
Methods
We analysed 632 patients enrolled between 01/2014 and 02/2018 in an ongoing registry that phenotypes and follows patients admitted for AHF. We compared CIED carriers with activated R-mode (CIED-R; n=37, 16% women) with CIED carriers not in R-mode (CIED-0; n=64, 23% women) and patients without CIEDs (no-CIED; n=511, 43% women). Information on survival status was collected up to 12 months after discharge from index hospitalisation (IH). Uni- and multivariable Cox proportional hazard regression was used to identify predictors of 12-month mortality risk.
Results
Mean age of the study sample was 74 (11) years, 39% were women, median LVEF on admission was 51 (quartiles 32, 59) % and de novo HF was detected in 20% of all patients. Median length of IH was 10 (7, 14) days. In-hospital mortality was similar across groups, but 12-month mortality risk was affected by chronotropic incompetence as indicated by R-mode activation: age- and sex-associated hazard ratio (HR) for CIED-R was 2.61 (95% CI 1.59–4.29, p<0.001) compared to group no-CIED, and 2.44 (95% CI 1.25–4.74, p=0.009) compared to group CIED-0. Amongst univariable predictors of mortality risk, strong associations were found for NT-proBNP levels (p<0.001), Charlson comorbidity index (p=0.001), and de novo HF (p=0.003). These effects persisted after multivariable adjustment for comorbidity burden. Within CIED-R, mortality risk was similar in patients with pacemakers vs. ICDs (HR 1.20, 95% CI 0.49–2.95) and in subgroups with LVEF <50% vs. ≥50% (HR 1.10, 95% CI 0.79–1.53). Mean heart rate on admission was lower in CIED-R vs. CIED-0 or no-CIED (70 bpm vs. 80 bpm or 82 bpm; both p<0.001). Heart rate on admission had no impact on frequency of in-hospital worsenings or death. However, we found a 36% increase in mortality risk per tertile of heart rate at discharge (HR 1.36, 95% CI 1.10–1.69, p=0.004) after exclusion of patients with an activated R-mode.
Conclusion
In AHF, R-mode stimulation was associated with an increased 12-month mortality risk, independent of LVEF, type of CIED, burden of comorbidities and type of presentation. Further, increased resting heart rate at discharge predicted 12-month mortality risk only in patients without an activated R-mode. Our findings suggest that chronotropic incompetence per se worsens outcome in AHF and may not be adequately treated through accelerometer-based R-mode stimulation.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): The Comprehensive Heart Failure Centre (CHFC) Würzburg is funded by the Federal Ministry of Education and Research, Integrated Research and Treatment Centre “Prevention of Heart Failure and its Complications”.
Collapse
Affiliation(s)
- M Huttelmaier
- University Hospital Wuerzburg, Department of Internal Medicine 1 , Wuerzburg , Germany
| | - S Muensterer
- University of Wuerzburg, Comprehensive Heart Failure Centre (CHFC) Würzburg , Wuerzburg , Germany
| | - C Morbach
- University of Wuerzburg, Comprehensive Heart Failure Centre (CHFC) Würzburg , Wuerzburg , Germany
| | - F Sahiti
- University of Wuerzburg, Comprehensive Heart Failure Centre (CHFC) Würzburg , Wuerzburg , Germany
| | - N Scholz
- University of Wuerzburg, Comprehensive Heart Failure Centre (CHFC) Würzburg , Wuerzburg , Germany
| | - J Albert
- University of Wuerzburg, Comprehensive Heart Failure Centre (CHFC) Würzburg , Wuerzburg , Germany
| | - C Angermann
- University of Wuerzburg, Comprehensive Heart Failure Centre (CHFC) Würzburg , Wuerzburg , Germany
| | - G Ertl
- University of Wuerzburg, Comprehensive Heart Failure Centre (CHFC) Würzburg , Wuerzburg , Germany
| | - S Frantz
- University Hospital Wuerzburg, Department of Internal Medicine 1 , Wuerzburg , Germany
| | - S Stoerk
- University of Wuerzburg, Comprehensive Heart Failure Centre (CHFC) Würzburg , Wuerzburg , Germany
| | - T Fischer
- University Hospital Wuerzburg, Department of Internal Medicine 1 , Wuerzburg , Germany
| |
Collapse
|
11
|
Christopher W, Nassoiy S, Marcus R, Keller J, Chang SC, Fischer T, Bilchik A, Goldfarb M. Prognostic indicators for undifferentiated carcinoma with/without osteoclast-like giant cells of the pancreas. HPB (Oxford) 2022; 24:1757-1769. [PMID: 35780038 DOI: 10.1016/j.hpb.2022.05.1344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 05/03/2022] [Accepted: 05/26/2022] [Indexed: 12/12/2022]
Abstract
BACKGROUND Undifferentiated carcinoma of the pancreas (UPC) is a rare malignancy. There are no standardized guidelines for treatment. Current management has been extrapolated from smaller reviews. METHODS 858 patients with UPC were identified in the 2004-2017 NCDB. Kaplan-Meier method followed by Cox proportional-hazards regression examined independent prognostic factors associated with overall survival (OS). Logistic regression analyses were performed to determine independent predictors of surgical intervention and the status of surgical resection by histologic subtype. RESULTS Patients with osteoclast-like giant cells (OCLGC) had a longer median OS compared to those without (aHR 0.52: 95% CI 0.41-0.67). Of the non-OCLGC subtypes, pleomorphic large cell demonstrated the shortest median OS (2.4 months). Surgical resection was associated with improved survival in all histologies except for pleomorphic cell carcinoma. R0 resection and negative lymph nodes were independently associated with an improved OS. CONCLUSION This is the largest database review published to date on UCP. OCLGC histology is associated with an improved survival compared to those without OCLGC. Of the non-OCLGC subtypes, pleomorphic large cell is associated with the shortest overall survival. Surgical resection is associated with a significant survival advantage for all histologies except for pleomorphic cell carcinoma.
Collapse
Affiliation(s)
| | - Sean Nassoiy
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | - Rebecca Marcus
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | - Jennifer Keller
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | | | - Trevan Fischer
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | - Anton Bilchik
- Providence St. John's Cancer Institute, Santa Monica, CA, USA
| | | |
Collapse
|
12
|
Garland-Kledzik M, Scholer A, Ensenyat-Mendez M, Orozco JIJ, Khader A, Santamaria-Barria J, Fischer T, Pigazzi A, Marzese DM. ASO Visual Abstract: Establishing Novel Molecular Subtypes of Appendiceal Cancer. Ann Surg Oncol 2021. [PMID: 34718914 DOI: 10.1245/s10434-021-10974-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Affiliation(s)
| | - Anthony Scholer
- Department of Surgery, John's Health Center, Saint John's Cancer Institute at Providence Street, Santa Monica, CA, USA
| | - Miquel Ensenyat-Mendez
- Cancer Cell Biology Group, Balearic Islands Health Research Institute (IdISBa), Palma, Islas Baleares, Spain
| | - Javier I J Orozco
- Cancer Epigenetics Laboratory, Saint John's Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA
| | - Adam Khader
- Department of Surgery, John's Health Center, Saint John's Cancer Institute at Providence Street, Santa Monica, CA, USA
| | - Juan Santamaria-Barria
- Department of Surgery, John's Health Center, Saint John's Cancer Institute at Providence Street, Santa Monica, CA, USA
| | - Trevan Fischer
- Department of Surgery, John's Health Center, Saint John's Cancer Institute at Providence Street, Santa Monica, CA, USA
| | - Alessio Pigazzi
- Colon and Rectal Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA
| | - Diego M Marzese
- Cancer Cell Biology Group, Balearic Islands Health Research Institute (IdISBa), Palma, Islas Baleares, Spain
| |
Collapse
|
13
|
Garland-Kledzik M, Scholer A, Ensenyat-Mendez M, Orozco JIJ, Khader A, Santamaria-Barria J, Fischer T, Pigazzi A, Marzese DM. Establishing Novel Molecular Subtypes of Appendiceal Cancer. Ann Surg Oncol 2021; 29:2118-2125. [PMID: 34718915 DOI: 10.1245/s10434-021-10945-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 09/24/2021] [Indexed: 01/03/2023]
Abstract
PURPOSE Appendiceal cancer is a rare disease process with complex treatment strategies. The objective of this study was to identify mutation-based genetic subtypes that may differ from the current histological classification, compare the genetic make-up of primaries and metastases, and find novel targetable alterations. METHODS The analyses involved the curation and normalization of gene mutation panels from appendiceal adenocarcinoma and mucinous adenocarcinoma (n = 196) stored in the AACR GENIE Database v6.0. Genes mutated in less than one patient and tumors profiled with incomplete mutation panels were excluded from the study. The optimal number of AC subtypes was established using the Nonnegative Matrix Factorization algorithm. Statistical comparisons of mutation frequencies were performed using Pearson's χ2 test. RESULTS AC patients were stratified into five mutation subtypes, based on a final set of 41 cancer-related genes. AC0 had no mutations. The most frequently mutated genes varied between the subtypes were: AC1: KRAS (91.9%) and GNAS (77.4%); AC2: KRAS (52.5%), APC (32.5%), and GNAS (30%); AC3: KMT2D (38.7%), TP53 (38.7%), KRAS (35.5%), EP300 (22.6%); and AC4: TP53 (97.2%), KRAS (77.8%), and SMAD4 (36.1%). Additionally, AC3 was less likely to be mucinous (22.6% vs. 50.0-74.2%, p < 0.001) and had a higher mutation frequency (3.6 vs. 0-3.1, p < 0.001). There were no significant differences between primary tumors and metastases in the 41 assessed genes (p = 0.35). CONCLUSIONS The characterization of these subtypes suggests a need for molecular approaches to complement anatomical and histopathological staging for AC. A prospective comparison of subtype prognosis and response to surgery and adjuvant treatment is needed to identify the clinical applications of the novel molecular subtypes.
Collapse
Affiliation(s)
| | - Anthony Scholer
- Department of Surgery, Saint John's Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA
| | - Miquel Ensenyat-Mendez
- Cancer Epigenetic Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, Islas Baleares, Spain
| | - Javier I J Orozco
- Cancer Epigenetics Laboratory, Saint John's Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA
| | - Adam Khader
- Department of Surgery, Saint John's Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA
| | - Juan Santamaria-Barria
- Department of Surgery, Saint John's Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA
| | - Trevan Fischer
- Department of Surgery, Saint John's Cancer Institute at Providence St. John's Health Center, Santa Monica, CA, USA
| | - Alessio Pigazzi
- Colon and Rectal Surgery, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA
| | - Diego M Marzese
- Cancer Epigenetic Laboratory, Health Research Institute of the Balearic Islands (IdISBa), Palma, Islas Baleares, Spain
| |
Collapse
|
14
|
Reinhold U, Bai-Habelski J, Abeck D, Denfeld R, Dominicus R, Fischer T, Radny P. [Potassium hydroxide 5 % solution in actinic keratosis : A novel therapeutic approach in the lesion-directed treatment]. Hautarzt 2021; 72:975-983. [PMID: 34387709 PMCID: PMC8536816 DOI: 10.1007/s00105-021-04888-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/04/2021] [Indexed: 11/29/2022]
Abstract
Hintergrund Die aktinische Keratose (AK) ist ein epitheliales Carcinoma in situ der Haut. Aufgrund des Risikos einer malignen Transformation besteht ein frühzeitiger Behandlungsbedarf. Gerade die initiale Therapie sollte neben der Wirksamkeit eine gute Verträglichkeit und Anwenderfreundlichkeit aufweisen. Kaliumhydroxid (KOH)-Lösung ist als keratolytische Behandlungsoption bei hyperkeratotischen Hauterkrankungen, wie z. B. Mollusca contagiosa, bereits etabliert. Methodik Wirksamkeit und Verträglichkeit von KOH-5 %-Lösung zur Behandlung der leichten bis moderaten AK wurden in einer prospektiven, einarmigen, multizentrischen Medizinproduktestudie (Treatment of AK with KOH [TAKKOH]) untersucht. Die KOH-Lösung wurde 2‑mal täglich über 14 Tage aufgetragen mit anschließender Behandlungspause von 14 Tagen (≙ 1 Behandlungszyklus) für maximal 3 Behandlungszyklen oder mindestens bis zum Behandlungserfolg. Das primäre Zielkriterium „Behandlungserfolg“ wurde als komplette Remission (CR) aller AK-Läsionen eines Patienten definiert. Sekundäre Zielkriterien beinhalteten die Beurteilung der partiellen Remission (PR), der Anzahl an AK-Läsionen in Remission, die Wirksamkeitsbeurteilung anhand von Schulnoten durch Prüfärzte und Patienten sowie sicherheitsrelevante Endpunkte. Ergebnisse Es wurden 73 Patienten in die Studie eingeschlossen. Eine CR wurde von 54,9 % der Patienten erreicht, eine PR von 64,8 % bei einer Reduktion der Gesamtzahl an Läsionen um 69,9 %. Bei 46,6 % der Patienten wurden unerwünschte Ereignisse beobachtet. Diese überwiegend unerwünschten Wirkungen (82,6 %) stellten ausnahmslos transiente und milde lokale Hautreaktionen dar. Schlussfolgerung Die Studie liefert Hinweise auf die Wirksamkeit und Sicherheit von KOH-5 %-Lösung zur läsionsgerichteten topischen Therapie der AK.
Collapse
Affiliation(s)
- U Reinhold
- MVZ Dermatologisches Zentrum Bonn GmbH, Friedensplatz 16, 53111, Bonn, Deutschland.
| | - J Bai-Habelski
- MVZ Dermatologisches Zentrum Bonn GmbH, Friedensplatz 16, 53111, Bonn, Deutschland
| | - D Abeck
- Hautzentrum Nymphenburg, Renatastr. 72, 80639, München, Deutschland
| | - R Denfeld
- , Werderstr. 66, 70190, Stuttgart, Deutschland
| | - R Dominicus
- Hautzentrum Dülmen, Vollenstr. 8, 48249, Dülmen, Deutschland
| | - T Fischer
- Haut- und Lasercentrum Potsdam, Kurfürstenstr. 40, 14467, Potsdam, Deutschland
| | - P Radny
- Derma-Study-Center Friedrichshafen GmbH, Charlottenstr. 12/1, 88045, Friedrichshafen, Deutschland
| |
Collapse
|
15
|
Fischer T, Schmid C, Kompis M, Mantokoudis G, Caversaccio M, Wimmer W. Effects of temporal fine structure preservation on spatial hearing in bilateral cochlear implant users. J Acoust Soc Am 2021; 150:673. [PMID: 34470279 DOI: 10.1121/10.0005732] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Accepted: 07/02/2021] [Indexed: 06/13/2023]
Abstract
Typically, the coding strategies of cochlear implant audio processors discard acoustic temporal fine structure information (TFS), which may be related to the poor perception of interaural time differences (ITDs) and the resulting reduced spatial hearing capabilities compared to normal-hearing individuals. This study aimed to investigate to what extent bilateral cochlear implant (BiCI) recipients can exploit ITD cues provided by a TFS preserving coding strategy (FS4) in a series of sound field spatial hearing tests. As a baseline, we assessed the sensitivity to ITDs and binaural beats of 12 BiCI subjects with a coding strategy disregarding fine structure (HDCIS) and the FS4 strategy. For 250 Hz pure-tone stimuli but not for broadband noise, the BiCI users had significantly improved ITD discrimination using the FS4 strategy. In the binaural beat detection task and the broadband sound localization, spatial discrimination, and tracking tasks, no significant differences between the two tested coding strategies were observed. These results suggest that ITD sensitivity did not generalize to broadband stimuli or sound field spatial hearing tests, suggesting that it would not be useful for real-world listening.
Collapse
Affiliation(s)
- T Fischer
- Department of ENT, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010 Bern, Switzerland
| | - C Schmid
- Department of ENT, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010 Bern, Switzerland
| | - M Kompis
- Department of ENT, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010 Bern, Switzerland
| | - G Mantokoudis
- Department of ENT, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010 Bern, Switzerland
| | - M Caversaccio
- Department of ENT, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010 Bern, Switzerland
| | - W Wimmer
- Department of ENT, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010 Bern, Switzerland
| |
Collapse
|
16
|
Khader A, Fischer T. Response to: Is there any association between a delay in surgery and nodal positivity in the ER-negative Her2 negative breast cancer subgroups? J Surg Oncol 2021; 124:155. [PMID: 33844863 DOI: 10.1002/jso.26486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Revised: 03/27/2021] [Accepted: 03/29/2021] [Indexed: 11/11/2022]
Affiliation(s)
- Adam Khader
- John Wayne Cancer Institute, Santa Monica, California, USA
| | - Trevan Fischer
- John Wayne Cancer Institute, Santa Monica, California, USA
| |
Collapse
|
17
|
Khader A, Chang SC, Santamaria-Barria J, Garland-Kledzik M, Scholer A, Goldfarb M, Grumley J, Fischer T. Delay in surgery is associated with axillary upstaging of clinically node negative breast cancer patients. J Surg Oncol 2020; 123:854-865. [PMID: 33333624 DOI: 10.1002/jso.26332] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 11/07/2020] [Accepted: 11/29/2020] [Indexed: 12/30/2022]
Abstract
BACKGROUND AND OBJECTIVES Most breast cancer (BC) patients present with early disease and clinically negative lymph nodes (cN0). Timing of surgery has not been standardized. We hypothesized that surgical delay results in an increased likelihood of nodal metastasis. METHODS Patients diagnosed with cN0 BC undergoing surgery with sentinel lymph node biopsy as initial therapy between 2006 and 2014 were identified in the NCDB and divided into four groups based on time intervals between diagnosis and surgery (<4 weeks, 4-8 weeks, 8-12 weeks, and >12 weeks). Regression analysis evaluated the independent impact of surgical timing on axillary upstaging and survival. RESULTS Of 355,443 patients with cN0 BC, 39.6% had surgery within 4 weeks and 5.4% more than 12 weeks from diagnosis. After controlling for relevant factors, a month delay in surgery was associated with an increased likelihood of nodal positivity (odds ratio: 1.04; 95% confidence interval [CI]: 1.04-1.05; p < .001) and decreased overall survival (hazard ratio: 1.03; 95% CI: 1.02-1.04; p < .001). When compared to patients who underwent surgery less than 4 weeks from diagnosis, the absolute increase in nodal positivity and relative risks were 5.3% (95% CI: 0.047-0.059) and 1.34 (95% CI: 1.30-1.38), respectively, in the more than 12 weeks group. CONCLUSIONS Delay in BC surgery in cN0 patients was associated with an increased likelihood of axillary upstaging and decreased survival.
Collapse
Affiliation(s)
- Adam Khader
- Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA
| | - Shu-Ching Chang
- Department of Biostatistics, Medical Data Research Center at Providence Health and Services Center, Portland, Oregon, USA
| | - Juan Santamaria-Barria
- Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA
| | - Mary Garland-Kledzik
- Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA
| | - Anthony Scholer
- Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA
| | - Melanie Goldfarb
- Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA
| | - Janie Grumley
- Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA
| | - Trevan Fischer
- Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, USA
| |
Collapse
|
18
|
Fahlberg MD, Blair RV, Doyle-Meyers LA, Midkiff CC, Zenere G, Russell-Lodrigue KE, Monjure CJ, Haupt EH, Penney TP, Lehmicke G, Threeton BM, Golden N, Datta PK, Roy CJ, Bohm RP, Maness NJ, Fischer T, Rappaport J, Vaccari M. Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates. Nat Commun 2020; 11:6078. [PMID: 33247138 PMCID: PMC7695721 DOI: 10.1038/s41467-020-19967-4] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2020] [Accepted: 11/03/2020] [Indexed: 01/08/2023] Open
Abstract
Understanding SARS-CoV-2 associated immune pathology is crucial to develop pan-effective vaccines and treatments. Here we investigate the immune events from the acute state up to four weeks post SARS-CoV-2 infection, in non-human primates (NHP) with heterogeneous pulmonary pathology. We show a robust migration of CD16 expressing monocytes to the lungs occurring during the acute phase, and we describe two subsets of interstitial macrophages (HLA-DR+CD206-): a transitional CD11c+CD16+ cell population directly associated with IL-6 levels in plasma, and a long-lasting CD11b+CD16+ cell population. Trafficking of monocytes is mediated by TARC (CCL17) and associates with viral load measured in bronchial brushes. We also describe associations between disease outcomes and high levels of cell infiltration in lungs including CD11b+CD16hi macrophages and CD11b+ neutrophils. Accumulation of macrophages is long-lasting and detectable even in animals with mild or no signs of disease. Interestingly, animals with anti-inflammatory responses including high IL-10:IL-6 and kynurenine to tryptophan ratios show less severe illness. Our results unravel cellular mechanisms of COVID-19 and suggest that NHP may be appropriate models to test immune therapies.
Collapse
Affiliation(s)
- M D Fahlberg
- Tulane National Primate Research Center, Covington, LA, USA
| | - R V Blair
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Pathology and Laboratory Animal Medicine, Tulane University School of Medicine, New Orleans, LA, USA
| | - L A Doyle-Meyers
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
| | - C C Midkiff
- Tulane National Primate Research Center, Covington, LA, USA
| | - G Zenere
- Tulane National Primate Research Center, Covington, LA, USA
| | - K E Russell-Lodrigue
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
| | - C J Monjure
- Tulane National Primate Research Center, Covington, LA, USA
| | - E H Haupt
- Tulane National Primate Research Center, Covington, LA, USA
| | - T P Penney
- Tulane National Primate Research Center, Covington, LA, USA
| | - G Lehmicke
- Tulane National Primate Research Center, Covington, LA, USA
| | - B M Threeton
- Tulane National Primate Research Center, Covington, LA, USA
| | - N Golden
- Tulane National Primate Research Center, Covington, LA, USA
| | - P K Datta
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Pathology and Laboratory Animal Medicine, Tulane University School of Medicine, New Orleans, LA, USA
| | - C J Roy
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA
| | - R P Bohm
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
| | - N J Maness
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA
| | - T Fischer
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA
| | - J Rappaport
- Tulane National Primate Research Center, Covington, LA, USA
- Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA
| | - M Vaccari
- Tulane National Primate Research Center, Covington, LA, USA.
- Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA.
| |
Collapse
|
19
|
Pabel S, Knierim M, Alebrand F, Paulus M, Herting J, Hollemann D, Sedej S, Von Lewinski D, Fischer T, Schmid C, Hasenfuss G, Brochhausen C, Maier L, Streckfuss-Boemeke K, Sossalla S. Atrial fibrillation impairs ventricular function by altering excitation-contraction coupling in the human heart. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Atrial fibrillation (AF) often co-exists in patients with heart failure (HF). Recent clinical evidence suggests that the arrhythmic component of AF alone may contribute to ventricular dysfunction. However, the pathophysiological effects of a non-tachycardic AF on the human ventricle are unknown. To investigate the effects of normofrequent AF on the human ventricle we investigated ventricular myocardium from patients with preserved ejection fraction with sinus rhythm (SR) or AF in the absence of HF (compensated hypertrophy, EF>50%, matched clinical characteristics). In histological analysis we detected no difference between SR (n=9) vs. AF (n=6) regarding the amount and distribution of fibrosis. For functional investigation, Ca-handling was studied (Fura-2 AM). While systolic Ca-transient amplitude was in trend reduced in isolated human ventricular AF cardiomyocytes, we found a significantly prolonged Ca-elimination time (n=17–22 cells/4 pat.). Using caffeine application, a decreased SR Ca-load in AF was detected, which may be explained by a significant decrease in SERCA2a activity (ksys-kCaff, n=10–12/4 pat.). Patch-clamp experiments revealed a prolonged action potential duration in AF cardiomyocytes (n=5/15 cells).
For the standardized evaluation of the mechanisms of persistent normofrequent arrhythmia, we simulated AF in vitro by using arrhythmic (1 Hz, 40% R-R-variability) or rhythmic (1 Hz) field stimulation. We performed contractility experiments using in-toto isolated human ventricular trabeculae from explanted human hearts. After 8h of pacing, arrhythmically stimulated human trabeculae showed a significantly reduced systolic force, an increase in diastolic tension and a prolonged relaxation (n=11–12 trabeculae/11 pat.). For studying the cellular effects of persistent normofrequent arrhythmia in a model suitable for chronic pacing (up to 7 days), we utilized human iPSC cardiomyocytes (iPSC-CM) from healthy donors (n=6). After 7 days, arrhythmic paced iPSC-CM showed a significantly reduced systolic Ca-transient amplitude, a prolonged Ca-elimination time (n=35/45 cells) as well as a reduced SR Ca-load and a trend towards a lower SERCA2a activity compared to control (n=11 cells). Confocal line-scans (Fluo-4 AM) showed an increased diastolic SR Ca-release, which might also explain the reduced SR Ca-content (n=45/35 cells). Moreover, in irregularly paced iPSC-CM we found significant increased levels of cytosolic Na (n=69 cells each) and in patch-clamp experiments a significantly prolonged action potential duration (n=14/11 cells/3 diff.).
This study demonstrates that a normofrequent arrhythmic ventricular excitation as it occurs in AF impairs human ventricular myocardial function by altering cardiomyocyte excitation-contraction coupling. Thus, this study provides the first translational mechanistic characterization and the potential negative impact of isolated AF in the absence of tachycardia on the human ventricle.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- S Pabel
- University hospital Regensburg, Regensburg, Germany
| | - M Knierim
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - F Alebrand
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - M Paulus
- University hospital Regensburg, Regensburg, Germany
| | - J Herting
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - D Hollemann
- University of Regensburg, Institute of Pathology, Regensburg, Germany
| | - S Sedej
- Medical University of Graz, Department of Cardiology, Graz, Austria
| | - D Von Lewinski
- Medical University of Graz, Department of Cardiology, Graz, Austria
| | - T Fischer
- University Hospital Wuerzburg, Wuerzburg, Germany
| | - C Schmid
- University hospital Regensburg, Regensburg, Germany
| | - G Hasenfuss
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - C Brochhausen
- University of Regensburg, Institute of Pathology, Regensburg, Germany
| | - L Maier
- University hospital Regensburg, Regensburg, Germany
| | - K Streckfuss-Boemeke
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - S Sossalla
- University hospital Regensburg, Regensburg, Germany
| |
Collapse
|
20
|
Emmert S, van Welzen A, Masur K, Gerling T, Bekeschus S, Eschenburg C, Wahl P, Bernhardt T, Schäfer M, Semmler ML, Grabow N, Fischer T, Thiem A, Jung O, Boeckmann L. Kaltes Atmosphärendruckplasma zur Behandlung akuter und chronischer Wunden. Hautarzt 2020; 71:855-862. [DOI: 10.1007/s00105-020-04696-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
21
|
Emmert S, Panzer R, Rode S, Thiem A, Tietze J, Blaschke V, Fischer T, Böckmann L. Die Klinik und Poliklinik für Dermatologie und Venerologie der Universitätsmedizin Rostock – von Fischschuppenerkrankungen, Mondscheinkindern und viel, viel Mee(h)r! Aktuelle Dermatologie 2020. [DOI: 10.1055/a-1147-3103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
ZusammenfassungDie Universität Rostock und die Universitätsmedizin als Gründungsfakultät ist die drittälteste Alma Mater in Mitteleuropa – 2019 hat sie ihr 600-jähriges Bestehen gefeiert. Die Klinik und Poliklinik für Dermatologie und Venerologie der Universitätsmedizin Rostock kann auf eine ähnlich lange Tradition zurückblicken – sie ist das drittälteste Ordinariat nach Breslau und der Charité in Berlin. Gemäß dem universitären Motto „Traditio et Innovatio“ hat sich aus dieser Tradition, begründet durch angesehene Ordinarien wie Wolters, Frieboes oder auch Flegel zu DDR-Zeiten, in den letzten 4 Jahren eine moderne universitäre Dermatologische Universitätsklinik (DUK) mit hoher Entwicklungsdynamik und einem Masterplan DUK2030 für alle Bereiche der Krankenversorgung, Forschung und Lehre entwickelt. Unter einem Dach sind stationäre, teilstationäre, ambulante und operative Patientenversorgung zusammen mit dem histologischen und klinischen Labor und den Forschungslaboren vereint. Unter anderem durch Zentrumsgründungen vor Ort (Hautkrebszentrum, Immuntherapiezentrum, Allergologisches Zentrum, Gefäß- und Wundzentrum, Zentrum für Seltene (Haut-) Erkrankungen) und auf europäischer Ebene (Europäisches Referenznetzwerkzentrum für seltene Hauterkrankungen) hat diese interdisziplinäre Zusammenarbeit die Klinik lokal und überregional sehr gut vernetzt. Ein junges, hochengagiertes und noch expandierendes Team hat diese bisherige Entwicklung ermöglicht. Dafür kann allen Beteiligten nicht genug gedankt werden. Dieser und die folgenden Artikel geben einen Einblick in die dermatologische Welt der Universitätsmedizin Rostock.
Collapse
Affiliation(s)
- S. Emmert
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - R. Panzer
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - S. Rode
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - A. Thiem
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - J. Tietze
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - V. Blaschke
- Leiter Medizincontrolling, Universitätsmedizin Rostock
| | - T. Fischer
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - L. Böckmann
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| |
Collapse
|
22
|
Boeckmann L, Bernhardt T, Schäfer M, Semmler ML, Glatzel A, Martens MC, Ulrich M, Thiem A, Tietze J, Jung O, Panzer R, Fischer T, Emmert S. Experimentelle Forschung an der Klinik und Poliklinik für Dermatologie und Venerologie. Aktuelle Dermatologie 2020. [DOI: 10.1055/a-1147-5015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
ZusammenfassungSeit Antritt von Prof. Dr. med. Steffen Emmert als Ordinarius der Klinik und Poliklinik für Dermatologie und Venerologie im Jahr 2015 konnte das dermatologische Forschungslabor sukzessive aufgebaut und erweitert werden. Im Einklang mit dem onkologischen Schwerpunkt der Universitätsmedizin Rostock sowie dem von der Landesregierung forcierten „Gesundheitsland Mecklenburg-Vorpommern“ wird grundlagenorientierten und translationalen Projekten nachgegangen. Das vorwiegend drittmittelfinanzierte und stetig wachsende Forschungsteam bearbeitet diverse Fragestellungen in den Bereichen der Dermato-Onkologie, Plasmamedizin und seltenen Hauterkrankungen. Inzwischen auf einem soliden Fundament stehend, befindet sich der Forschungsbereich weiterhin in einem dynamischen Entwicklungsprozess. Nicht nur personell, sondern auch thematisch und methodisch wird er derzeit durch die Integration weiterer Arbeitsgruppen unter der Leitung von Ärzten aus der Klinik ergänzt und ausgebaut. Diverse Kollaborationen an der Universitätsmedizin Rostock und im Land zeugen von einem freundlichen, unterstützenden und kollegialen Umfeld, das die Integration am Standort befördert hat.
Collapse
Affiliation(s)
- L. Boeckmann
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - T. Bernhardt
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - M. Schäfer
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - M. L. Semmler
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - A. Glatzel
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - M. C. Martens
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - M. Ulrich
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - A. Thiem
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - J. Tietze
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - O. Jung
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - R. Panzer
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - T. Fischer
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| | - S. Emmert
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock
| |
Collapse
|
23
|
Scholer AJ, Uppal A, Chang SC, Ghosh D, Garland-Kledzik M, Santamaria-Barria J, Khader A, Dehal A, Fischer T, Goldfarb M. Inaccurate pretreatment staging can impact survival in early stage esophageal adenocarcinoma. J Surg Oncol 2020; 122:914-922. [PMID: 32632944 DOI: 10.1002/jso.26101] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2020] [Accepted: 06/15/2020] [Indexed: 12/29/2022]
Abstract
BACKGROUND Given the survival advantage of neoadjuvant treatment for locally advanced esophageal cancer, accurate clinical staging is necessary. The aim of this study was to assess the clinical (c) and pathologic (p) staging concordance rates for presumably early stage esophageal adenocarcinoma patients that had upfront esophagectomy (UFE) and evaluate if survival (OS) was negatively affected by inaccurate preoperative staging and subsequent treatment selection. METHODS An NCDB retrospective review of nonmetastatic esophageal adenocarcinoma patients that had UFE. The rates of concordance between c and p staging system and OS were calculated. RESULTS Of 2775 patients, most patients presented with cN0 (82.8%) and cT1 tumors (53.6%). The overall concordance between c and p staging was 78.8% for T-classification (moderate agreement; weighted κ = 0.729; P < .001) and 78.8% for N-classification (weak agreement; weighted κ = 0.448; P < .001). Patients that were upstaged due to a lack of concordance between T-classification had decreased 5- and 10-year OS (30% and 16%, P < .001) and those upstaged due to discordant N-classification had decreased 5- and 10-year OS (28% and 23%, P < .001)." CONCLUSIONS Preoperative staging of esophageal adenocarcinoma has moderate reliability and accuracy for predicting pT and pN classification. Up to 25% of patients have discordant clinical and pathological staging, which impacts OS.
Collapse
Affiliation(s)
- Anthony J Scholer
- Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California
| | - Abhineet Uppal
- Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California
| | - Shu-Ching Chang
- Medical Data Research Center, Providence Health and Services Oregon and Southwest Washington, Portland, Oregon
| | - Debopriya Ghosh
- Rutgers Institute of Data Science, Learning, and Applications, Rutgers University, Newark, New Jersey
| | - Mary Garland-Kledzik
- Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California
| | | | - Adam Khader
- Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California
| | - Ahmed Dehal
- Department of Surgery, Kaiser Permanente Southern California, Pasadena, California
| | - Trevan Fischer
- Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California
| | - Melanie Goldfarb
- Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, California
| |
Collapse
|
24
|
Boeckmann L, Bernhardt T, Schäfer M, Semmler ML, Kordt M, Waldner AC, Wendt F, Sagwal S, Bekeschus S, Berner J, Kwiatek E, Frey A, Fischer T, Emmert S. [Current indications for plasma therapy in dermatology]. Hautarzt 2020; 71:109-113. [PMID: 31965204 DOI: 10.1007/s00105-019-04530-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND Plasma medicine is gaining increasing interest and provides a multitude of dermatological applications. Cold atmospheric pressure plasma (CAP) can be used in clinical applications without harming the treated tissue or in a tissue destructive manner. It consists of a complex mixture of biologically active agents, which can act synergistically on the treated material or tissue. OBJECTIVES A summary of the current research findings regarding dermatological applications of CAP is provided. METHODS Literature on CAP applications in dermatology has been screened and summarized. RESULTS CAP exerts antimicrobial, tissue-stimulating, blood-flow-stimulating but also pro-apoptotic effects. By exploiting these properties, CAP is successfully applied for disinfection and treatment of chronic ulcerations. Furthermore, positive effects of CAP have been shown for the treatment of tumors, actinic keratosis, scars, ichthyosis, atopic eczema as well as for alleviation of pain and itch. CONCLUSIONS While the use of CAP for disinfection and wound treatment has already moved into clinical practice, further applications such as cancer treatment are still exploratory.
Collapse
Affiliation(s)
- L Boeckmann
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland
| | - T Bernhardt
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland
| | - M Schäfer
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland
| | - M Luise Semmler
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland
| | - M Kordt
- Rudolf-Zenker-Institut für Experimentelle Chirurgie, Universitätsmedizin Rostock, Rostock, Deutschland
| | - A-C Waldner
- Arbeitsbereich Zellbiologie, Universitätsmedizin Rostock, Rostock, Deutschland
| | - F Wendt
- Institut für Pharmakologie und Toxikologie, Universitätsmedizin Rostock, Rostock, Deutschland
| | - S Sagwal
- Leibniz-Institut für Plasmaforschung und Technologie e. V., Greifswald, Deutschland
| | - S Bekeschus
- Leibniz-Institut für Plasmaforschung und Technologie e. V., Greifswald, Deutschland
| | - J Berner
- Klinik und Poliklinik für Mund-Kiefer-Gesichtschirurgie/Plastische Operationen, Universitätsmedizin Greifswald, Greifswald, Deutschland
| | - E Kwiatek
- Klinik und Poliklinik für Mund-Kiefer-Gesichtschirurgie/Plastische Operationen, Universitätsmedizin Greifswald, Greifswald, Deutschland
| | - A Frey
- Institut für Chemie, Universität Rostock, Rostock, Deutschland
| | - T Fischer
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland
| | - S Emmert
- Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsmedizin Rostock, Strempelstr. 13, 18057, Rostock, Deutschland.
| |
Collapse
|
25
|
Salatzki J, Fischer T, Ochs M, Fortner P, Hirschberg K, Andre F, Katus H, Riffel J. P5259Evaluation of functional impairment and cardiac remodelling in isolated left branch bundle block using magnetic resonance imaging. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Left bundle-branch block (LBBB) is associated with underlying cardiovascular abnormalities, such as dilated cardiomyopathy and coronary heart disease. However, an isolated LBBB can be found in individuals without detectable cardiovascular disease. Echocardiographic studies demonstrated a reduced left ventricular (LV) ejection fraction (EF) and an increased LV cavity volume and mass in patients with isolated LBBB. Recent studies have shown larger cavity volumes (end-diastolic volume – EDV; end-systolic volume – ESV) and lower LVEF using CMR. However, there is still limited data on cardiac function, volumes and mass and the correlation between the parameters and the QRS duration (QRS) in patients with isolated LBBB.
Purpose
In this retrospective study LV function, volume, mass, T1-values and myocardial strain were measured and correlation between QRS duration in patients with isolated LBBB was identified using CMR.
Methods
Potential cases were identified from our local database, who underwent CMR during 2015–2018. We excluded patients with echocardiographic abnormalities besides abnormal septal motion or greater than a mild valve disease, known cardiovascular disease (coronary artery disease, cardiomyopathy or arrhythmia), history of potential cardiotoxic chemotherapy. We could identify 26 adults, who underwent CMR in a 1.5- or 3-Tesla scanner. LBBB was confirmed by ECG prior to CMR by a cardiologist. T1-values (MOLLI) were available in 19 patients. Myocardial strain (tissue tracking) could be performed in 23 patients. Associations were tested using Pearson's correlation analysis.
Results
26 patients (age 61.5±9.6 years, 19 women, BMI 25.4 (18.2–38.1)) with isolated LBBB were included (QRS duration: 138±12ms). CMR results in the cohort revealed a reduced LVEF (53.4±3,8%) and slightly enlarged LV cavity when corrected to body-surface area (BSA) (LV-EDV/BSA: 83.7±13.8ml/m2; LV-ESV/BSA: 39.3±8.6ml/m2), when compared to normal values from the study center. There is a negative correlation between LVEF and QRS duration (r=−0.550, p<0.05) and a positive correlation between QRS duration and LV-EDV/BSA (r=0.627, p<0.05) as well as between QRS and LV-ESV/BSA (r=0.661, p<0.05). In addition, there is a positive correlation between QRS duration and myocardial mass (r=0.645, p<0.05), septal myocardial thickness (r=0.405, p<0.05) and lateral wall thickness (r=0.495, p<0.05). In addition, there is a positive correlation between LV longitudinal strain and QRS (r=0.449, p<0.05). T1-values were in normal range. There is no correlation between QRS and T1-values.
Conclusion
Using CMR a negative correlation between LV function and QRS duration and the positive correlation between LV volumes and QRS duration in patients with isolated LBBB could be identified. The absence of significant myocardial fibrosis with normal T1-values indicates an electromechanical dissociation rather than an underlying myocardial abnormality as an explanation for the reduced LVEF.
Collapse
Affiliation(s)
- J Salatzki
- University of Heidelberg, Heidelberg, Germany
| | - T Fischer
- University of Heidelberg, Department of Cardiology, Angiology and Pneumology, Heidelberg, Germany
| | - M Ochs
- University of Heidelberg, Department of Cardiology, Angiology and Pneumology, Heidelberg, Germany
| | - P Fortner
- University of Heidelberg, Department of Cardiology, Angiology and Pneumology, Heidelberg, Germany
| | - K Hirschberg
- University of Heidelberg, Department of Cardiology, Angiology and Pneumology, Heidelberg, Germany
| | - F Andre
- University of Heidelberg, Department of Cardiology, Angiology and Pneumology, Heidelberg, Germany
| | - H Katus
- University of Heidelberg, Department of Cardiology, Angiology and Pneumology, Heidelberg, Germany
| | - J Riffel
- University of Heidelberg, Department of Cardiology, Angiology and Pneumology, Heidelberg, Germany
| |
Collapse
|
26
|
Schlack K, Boegemann M, Woike M, Krekeler G, Fischer T, Bergmann L, Rink M, Schmid M, Strauss A. Effect of antacid intake on the therapeutic efficacy of sunitinib (SUN) in metastatic renal cell carcinoma (mRCC) patients (pts): A sub-analysis of the STAR-TOR registry. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Eiringhaus J, Wuensche C, Herting J, Hasenfuss G, Sossalla S, Fischer T. P3829Antiarrhythmic effects of Sacubitrilat (LBQ657) on Ca2+ homeostasis in ventricular cardiomyocytes. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background and objectives
Simultaneous inhibition of neprilysin and angiotensin II receptors by sacubitril/valsartan was shown to significantly reduce morbidity and mortality in heart failure patients compared to sole interference with the renin angiotensin system. Beneficial effects of increased levels of natriuretic peptides following neprilysin inhibition have been suggested, whereas direct effects of sacubitrilat on myocardial Ca2+ cycling properties remain elusive.
Methods and results
Under basal conditions the combination of active neprilysin-inhibitior sacubitrilat (LBQ657) and angiotensin II receptor inhibitor valsartan did not influence diastolic Ca2+ spark frequency (CaSpF) nor arrhythmogenic SR Ca2+ leak in murine ventricular cardiomyocytes (confocal microscopy, n CMs/hearts=80/7 vs. 100/7, P=0.91/0.99). In contrast, sacubitrilat/valsartan treatment significanty reduced CaSpF by 35±9% and SR Ca2+ leak by 45±9% in CMs that had been put under catecholaminergic stress (isoproterenol 10nM, n=81/7 vs. 62/7, P<0.001 both). This effect could be clearly be attributed to the neprilysin inhibitor sacubitrilat as sole sacubitrilat treatment also reduced both parameters by similar degrees (reduction of CaSpF by 57±7% and SR Ca2+ leak by 76±5%; n=101/4 vs. 108/4, P<0.01 both) whereas sole valsartan treatment did not affect diastolic SR Ca2+ leak. Of note, systolic Ca2+ release, SR Ca2+ load and Ca2+ transient kinetics of murine CMs were not compromised upon treatment with sacubitrilat (epifluorescence microscopy, n=41/6 vs. 39/6). Importantly, sacubitrilat/valsartan in combination as well as sacubitrilat alone also reduced diastolic CaSpF and SR Ca2+ leak by 40–74% in human left-ventricular CMs from patients with end-stage heart failure (n=71/8 vs. 78/8, P<0.05).
Conclusion
This study demonstrates that neprilysin-inhibition directly exerts beneficial effects on Ca2+ homeostasis in human heart failure. We can show for the first time that neprilysin-inhibition by sacubitrilat yields a strong reduction of arrhythmogenic SR Ca2+ leak without affecting systolic Ca2+ release. These effects might contribute to the mortality benefit of sacubitril/valsartan treatment in the PARADIGM Study.
Acknowledgement/Funding
THF was funded by the Deutsche Forschungsgemeinschaft (DFG) through the SFB 1002 (A11). SS is supported by the Marga und Walter Boll-Stiftung.
Collapse
Affiliation(s)
- J Eiringhaus
- Hannover Medical School, Dept. of Cardiology and Angiology, Hannover, Germany
| | - C Wuensche
- University clinic, Dept. of Cardiology & Pneumology, Goettingen, Germany
| | - J Herting
- University clinic, Dept. of Cardiology & Pneumology, Goettingen, Germany
| | - G Hasenfuss
- University clinic, Dept. of Cardiology & Pneumology, Goettingen, Germany
| | - S Sossalla
- University Hospital Regensburg, Dept. of Cardiology, Regensburg, Germany
| | - T Fischer
- University clinic, Dept. of Cardiology & Pneumology, Goettingen, Germany
| |
Collapse
|
28
|
Uppal A, Wang M, Fischer T, Goldfarb M. Duodenal GI stromal tumors: Is radical resection necessary? J Surg Oncol 2019; 120:940-945. [PMID: 31401812 DOI: 10.1002/jso.25672] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Accepted: 08/01/2019] [Indexed: 01/10/2023]
Abstract
BACKGROUND AND OBJECTIVES Duodenal gastrointestinal stromal tumors (GISTs) are rare tumors that pose a surgical challenge, and long-term outcomes after resection have not been detailed outside of small case series. This study uses the National Cancer Database (NCDB) to examine the determinants of radical resection for duodenal GISTs as well as the impact of local vs radical resection on overall survival (OS). METHODS The NCDB was queried for nonmetastatic duodenal GISTs from 2004 to 2014. Predictors of radical resection were determined using multivariate logistic regression stratified by extent of tumor involvement. Factors associated with OS were identified with Cox proportional regression analysis. RESULTS Treatment at an academic center, size >5 cm, and extra-duodenal extension were associated with radical resection. On multivariate analysis, radical resection was associated with decreased OS (HR, 1.93; P < .03). Systemic therapy, extra-duodenal extension, grade, stage, mitoses, and receipt of systemic therapy did not impact OS. CONCLUSION Local resection of duodenal GISTs is associated with improved OS compared to radical resection after controlling for tumor factors and systemic treatment. Traditional indicators of tumor aggressiveness were associated with radical resection, but not OS. When feasible, local resection should be considered for resection of duodenal GISTs.
Collapse
Affiliation(s)
- Abhineet Uppal
- Department of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Hospital, Santa Monica, California
| | - Mansen Wang
- Medical Data Research Center, Providence Saint Joseph's Health, Portland, Oregon
| | - Trevan Fischer
- Department of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Hospital, Santa Monica, California
| | - Melanie Goldfarb
- Department of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Hospital, Santa Monica, California
| |
Collapse
|
29
|
Jacobs VR, Fischer T. Vergleich der internen vs. Uni-basierten Qualitätssicherung der GYN-Vorlesung für Medizinstudierende im 3. Studienjahr 2018 an der PMU Salzburg. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- VR Jacobs
- Universitätsklinik für Geburtshilfe und Gynäkologie, Paracelsus Medical University, Salzburg, Österreich
| | - T Fischer
- Universitätsklinik für Geburtshilfe und Gynäkologie, Paracelsus Medical University, Salzburg, Österreich
| |
Collapse
|
30
|
Teng A, Nelson DW, Dehal A, Chang SC, Fischer T, Steele SR, Goldfarb M. Colon cancer as a subsequent malignant neoplasm in young adults. Cancer 2019; 125:3749-3754. [PMID: 31290995 DOI: 10.1002/cncr.32325] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 05/05/2019] [Accepted: 05/07/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND The incidence of colon cancer (CC) is rising in younger adults and can occur de novo or in patients previously treated for another cancer. To the authors' knowledge, the impact on survival of CC occurring as a subsequent malignant neoplasm (SMN) has not been described for younger patients, which the authors anticipate to be lower with SMNs than that of primary CC. METHODS Patients aged <50 years with CC in the 2004 through 2014 National Cancer Data Base were identified. Patients were stratified by primary or subsequent occurrence. The impact of SMN status on overall survival (OS) was evaluated. RESULTS Of 41,915 patients, 2852 (6.8%) had colon SMNs. More patients with colon SMNs were aged 40 to 49 years compared with patients with primary CC (83% vs 77%; P < .001). Patients with colon SMNs presented with earlier clinical and pathological T, N, and M classifications (all P < .001). Colon SMNs more commonly occurred in the right colon, whereas primary CC was found to have a higher prevalence in the sigmoid colon (P < .001). Patients with colon SMNs more frequently underwent total colectomy (17% vs 5%; P < .001), but received less chemotherapy (53% vs 65%; P < .001). When adjusted for demographic, tumor, and treatment characteristics, SMN status was associated with a 23% decreased OS compared with primary CC (95% CI, 1.14-1.31; P < .001). Chemotherapy offered a 33% improvement in OS (95% CI, 0.56-0.8; P < .001). CONCLUSIONS Colon SMNs in younger patients present at an earlier stage and are treated more aggressively surgically compared with primary CCs. Patients with SMNs of the colon have decreased survival, although chemotherapy offers a survival advantage. Further investigation is warranted to determine whether these disparities are due to the effects of cancer treatment or differences in tumor biology.
Collapse
Affiliation(s)
- Annabelle Teng
- Department of Surgical Oncology, John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California
| | - Daniel W Nelson
- Department of Surgical Oncology, John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California
| | - Ahmed Dehal
- Department of Surgical Oncology, John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California
| | - Shu-Ching Chang
- Medical Data Research Center, Providence St. Joseph Health, Portland, Oregon
| | - Trevan Fischer
- Department of Surgical Oncology, John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California
| | - Scott R Steele
- Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio
| | - Melanie Goldfarb
- Department of Surgical Oncology, John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California
| |
Collapse
|
31
|
Santamaria-Barria JA, Stern S, Khader A, Garland-Kledzik M, Scholer AJ, Fischer T, Bilchik A. Changing Trends in Industry Funding for Surgical Oncologists. Ann Surg Oncol 2019; 26:2327-2335. [DOI: 10.1245/s10434-019-07380-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2019] [Indexed: 12/21/2022]
|
32
|
Hunziker L, Radovanovic D, Jeger R, Pedrazzini G, Cuculi F, Urban P, Erne P, Rickli H, Pilgrim T, Hess F, Simon R, Hangartner P, Hufschmid U, Hornig B, Altwegg L, Trummler S, Windecker S, Rueff T, Loretan P, Roethlisberger C, Evéquoz D, Mang G, Ryser D, Müller P, Jecker R, Kistler W, Hongler T, Stäuble S, Freiwald G, Schmid H, Stauffer J, Cook S, Bietenhard K, Roffi M, Wojtyna W, Schönenberger R, Simonin C, Waldburger R, Schmidli M, Federspiel B, Weiss E, Marty H, Weber K, Zender H, Poepping I, Hugi A, Koltai E, Iglesias J, Erne P, Heimes T, Jordan B, Pagnamenta A, Feraud P, Beretta E, Stettler C, Repond F, Widmer F, Heimgartner C, Polikar R, Bassetti S, Iselin H, Giger M, Egger P, Kaeslin T, Fischer A, Herren T, Eichhorn P, Neumeier C, Flury G, Girod G, Vogel R, Niggli B, Yoon S, Nossen J, Stoller U, Veragut U, Bächli E, Weber A, Schmidt D, Hellermann J, Eriksson U, Fischer T, Peter M, Gasser S, Fatio R, Vogt M, Ramsay D, Wyss C, Bertel O, Maggiorini M, Eberli F, Christen S. Twenty-Year Trends in the Incidence and Outcome of Cardiogenic Shock in AMIS Plus Registry. Circ Cardiovasc Interv 2019; 12:e007293. [DOI: 10.1161/circinterventions.118.007293] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Lukas Hunziker
- Department of Cardiology, Bern University Hospital, Switzerland (L.H., T.P.)
| | - Dragana Radovanovic
- AMIS Plus Data Center, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland (D.R.)
| | - Raban Jeger
- Division of Cardiology, University Hospital Basel, Switzerland (R.J.)
| | | | - Florim Cuculi
- Heart Centre Lucerne, Luzerner Kantonsspital, Switzerland (F.C.)
| | - Philip Urban
- Cardiology Department, La Tour Hospital, Geneva, Switzerland (P.U.)
| | - Paul Erne
- Department of Biomedicine, University of Basel, Switzerland (P.E.)
| | - Hans Rickli
- Department of Cardiology, Kantonsspital St. Gallen, Switzerland (H.R.)
| | - Thomas Pilgrim
- Department of Cardiology, Bern University Hospital, Switzerland (L.H., T.P.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Lüftner D, Schuetz F, Schneeweiss A, Grischke EM, Bloch W, Decker T, Uleer C, Salat C, Förster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Guderian G, Hanson S, Fasching P. Abstract P6-18-08: Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the pivotal BOLERO-2 trial, everolimus (EVE) + exemestane (EXE) more than doubled the median progression-free survival (PFS) vs EXE alone in hormone receptor positive (HR+), human epidermal growth factor-receptor 2-negative (HER2-) advanced breast cancer (ABC) recurring/progressing on/after prior non-steroidal aromatase inhibitors (NSAIs). BRAWO is a German non-interventional study conducted in patients (pts) with HR+, HER2–ABC receiving EVE + EXE, according to Summary of Product Characteristics (SmPC), in routine clinical practice. Here we report the final PFS and safety results.
Methods: This multicenter study documented 2100 pts between October 2012 and December 2017 across 341 sites in Germany. Postmenopausal women with HR+, HER2– ABC with recurrence or progression after a NSAI were included. Primary observation parameters included the evaluation of the effectiveness of EVE + EXE used in routine care for the entire pt group.
Results: In the final analysis, out of the 2100 documented pts, 2074 were included in the full analysis set. The median time since the primary diagnosis was 7.1 years and the median time from first sign of relapse (local recurrence or distant metastases) was 2.1 years. At baseline, 54.1% of pts presented with visceral metastases and 50.1% had an ECOG performance status of 0. Approximately, 63% of pts started with EVE 10 mg (median duration of exposure: 5.1 months; 95% CI, 4.6-5.4), while 34.1% started with EVE 5 mg (median duration of exposure: 4.6 months; 95% CI, 4.1-5.2).
The distribution of treatment lines was as follows: first line, 28.7% (n=595); second line, 31.9% (n=662); third line, 18.1% (n=376); fourth line, 10.7% (n=221) and, fifth line and later, 10.6% (n=220). Treatment was discontinued by 55.7% of pts (n=1170) due to progressive disease and 26% of pts (n=546) due to adverse events. The Kaplan-Meier estimate of the median PFS was 6.6 months (95% CI, 6.2-7.0). The best overall responses, based on clinical routine, were complete response, 0.8% (n=17), partial response, 7.4% (n=150), and stable disease, 41.3% (n=842). The general safety profile was consistent with the previously reported safety findings. The most common adverse events were stomatitis (any grade: 42.6%, grade 3: 3.8%, grade 4: <0.1%) and fatigue (any grade: 19.8%, grade 3: 1.5%).
Conclusions: Data from BRAWO support EVE + EXE as a suitable treatment option with a reasonable safety profile for HR+, HER2− ABC recurring or progressing on/after prior NSAIs.
Citation Format: Lüftner D, Schuetz F, Schneeweiss A, Grischke E-M, Bloch W, Decker T, Uleer C, Salat C, Förster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Guderian G, Hanson S, Fasching P. Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-08.
Collapse
Affiliation(s)
- D Lüftner
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - F Schuetz
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - A Schneeweiss
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - E-M Grischke
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - W Bloch
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - T Decker
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C Uleer
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C Salat
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - F Förster
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - M Schmidt
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C Mundhenke
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - H Tesch
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C Jackisch
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - T Fischer
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - G Guderian
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - S Hanson
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - P Fasching
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| |
Collapse
|
34
|
Fischer T, Spohn M, Olearo F, Zinser ME, Kasonta R, Stubbe HC, Rechtien A, Ly ML, Schmiedel S, Lohse AW, Grundhoff A, Addo MM, Dahlke C. Dynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV. Vaccine 2018; 36:7083-7094. [PMID: 30244872 DOI: 10.1016/j.vaccine.2018.09.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Revised: 09/02/2018] [Accepted: 09/08/2018] [Indexed: 12/18/2022]
Abstract
VSV-EBOV is a replication-competent Ebola virus (EBOV) vaccine, which was tested in clinical trials as response to the Ebola virus disease (EVD) outbreak 2013-2016. It is the most advanced EBOV candidate currently in the licensure process. The experimental vaccine was again administered as response to outbreaks in the Democratic Republic of Congo. However, underlying molecular mechanisms that convey protection remain incompletely understood. MicroRNAs (miRNAs) are known key regulators that influence gene expression on a post-transcriptional level. The miRNA-mediated control has emerged as a critical regulatory principle in the immune system, which strongly influences the balance of innate and adaptive immune responses by modulation of signaling pathways critical for differentiation of immune cells. We investigated expression levels of circulating miRNAs (c-miRNAs) in plasma from healthy vaccinees, as they may reflect cellular dynamics following VSV-EBOV immunization and additionally may serve as potential biomarkers for vaccine efficacy. As part of the WHO-led VEBCON consortium, we investigated safety and immunogenicity of VSV-EBOV in a phase I trial. A comprehensive analysis of expression levels on c-miRNAs from plasma samples following VSV-EBOV immunization (day 0, 1, 3 post vaccination) was conducted using RT-qPCR assays. Potential biological relevance was assessed using in silico analyses. Additionally, we correlated dynamics of miRNA expressions with our previously reported data on vaccine-induced antibody and cytokine responses and finally evaluated the prognostic power by generating ROC curves. We identified four promising miRNAs (hsa-miR-146a, hsa-miR-126, hsa-miR-199a, hsa-miR-484), showing a strong association with adaptive immune responses, exhibited favourable prognostic performance and are implicated in immunology-related functions. Our results provide evidence that miRNAs may serve as useful biomarkers for prediction of vaccine-induced immunogenicity. Furthermore, our unique data set provides insight into molecular mechanisms that underlie VSV-EBOV-mediated protective immune responses, which may help to decipher VSV-EBOV immune signature and accelerate strategic vaccine design or personalized approaches.
Collapse
Affiliation(s)
- T Fischer
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Germany
| | - M Spohn
- Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany
| | - F Olearo
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany
| | - M E Zinser
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Germany
| | - Rahel Kasonta
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Germany
| | - H C Stubbe
- Division of Infectious Diseases, Department of Medicine II, LMU, Munich, Germany
| | - A Rechtien
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Germany; Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany
| | - M L Ly
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Germany; University Medical Center Hamburg-Eppendorf (UKE), Division of Infectious Diseases, Hamburg, Germany
| | - S Schmiedel
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; University Medical Center Hamburg-Eppendorf (UKE), Division of Infectious Diseases, Hamburg, Germany
| | - A W Lohse
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Germany
| | - A Grundhoff
- Heinrich-Pette-Institute, Leibniz Institute for Experimental Virology, Hamburg, Germany
| | | | - M M Addo
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Germany; University Medical Center Hamburg-Eppendorf (UKE), Division of Infectious Diseases, Hamburg, Germany.
| | - C Dahlke
- University Medical Center Hamburg-Eppendorf (UKE), 1st Department of Medicine, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems, Germany; University Medical Center Hamburg-Eppendorf (UKE), Division of Infectious Diseases, Hamburg, Germany.
| |
Collapse
|
35
|
Pabel S, Bollenberg H, Bengel P, Tirilomis P, Mustroph J, Wagner S, Fischer T, Streckfuss-Boemeke K, Maier L, Hasenfuss G, Hamdani N, Sossalla S. P1509Empagliflozin directly improves diastolic function in human heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1509] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Pabel
- University Hospital Regensburg, Internal Medicine II, Heart Center, Regensburg, Germany
| | - H Bollenberg
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - P Bengel
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - P Tirilomis
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - J Mustroph
- University Hospital Regensburg, Internal Medicine II, Heart Center, Regensburg, Germany
| | - S Wagner
- University Hospital Regensburg, Internal Medicine II, Heart Center, Regensburg, Germany
| | - T Fischer
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - K Streckfuss-Boemeke
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - L Maier
- University Hospital Regensburg, Internal Medicine II, Heart Center, Regensburg, Germany
| | - G Hasenfuss
- University Medical Center Gottingen (UMG), Dept. of Cardiology and Pneumology, Heart Center, Gottingen, Germany
| | - N Hamdani
- Ruhr University Bochum (RUB), Department of Cardiovascular Physiology, Bochum, Germany
| | - S Sossalla
- University Hospital Regensburg, Internal Medicine II, Heart Center, Regensburg, Germany
| |
Collapse
|
36
|
Köhler M, Hoppe S, Frommer J, Flechtner H, Kropf S, Lux A, Bartsch R, Holzner B, Krauter J, Grabietz P, Florschütz A, Hoelzer K, Jentsch-Ullrich K, Fischer T. Randomisierte klinische Studie zu einer Coping Support Intervention für Eltern von Adoleszenten und jungen Erwachsenen (AYA) mit hämatologischen Malignomen. Psychother Psychosom Med Psychol 2018. [DOI: 10.1055/s-0038-1667915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
37
|
Mahnkopf C, Mitlacher M, Busch S, Fischer T, Brachmann J, Forkmann M. P1888Left atrial cardiomyopathy is a progressive disease accelerated by atrial fibrillation: comparison between patients with and without atrial fibrillation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- C Mahnkopf
- Klinikum Coburg, Department of Cardiology, Coburg, Germany
| | - M Mitlacher
- Klinikum Coburg, Department of Cardiology, Coburg, Germany
| | - S Busch
- Klinikum Coburg, Department of Cardiology, Coburg, Germany
| | - T Fischer
- Klinikum Coburg, Department of Cardiology, Coburg, Germany
| | - J Brachmann
- Klinikum Coburg, Department of Cardiology, Coburg, Germany
| | - M Forkmann
- Klinikum Coburg, Department of Cardiology, Coburg, Germany
| |
Collapse
|
38
|
Higgins R, Jensen A, Wachstein J, Has C, Bruckner-Tuderman L, Spiegel R, Traber H, Achermann J, Schaller M, Röcken M, Ignatova D, Chang Y, Fischer T, French L, Hötzenecker W, Hornung R, Malzacher A, Cozzio A, Navarini A, Guenova E. 814 Uniparental inheritance of junctional epidermolysis bullosa (JEB) through mutation of ITGA6 and trisomic rescue. J Invest Dermatol 2018. [DOI: 10.1016/j.jid.2018.03.824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
39
|
Adair S, Baus M, Belknap J, Bell R, Boero M, Bussy C, Cardenas F, Casey T, Castro J, Davis W, Erskine M, Farr R, Fischer T, Forbes B, Ford T, Genovese R, Gottschalk R, Hoge M, Honnas C, Hunter G, Joyce J, Kaneps A, Keegan K, Kramer J, Lischer C, Marshall J, Oosterlinck M, Radue P, Redding R, Reed SK, Rick M, Santschi E, Schoonover M, Schramme M, Schumacher J, Stephenson R, Thaler R, Vedding Neilsen J, Wilson DA. Response to Letter to the Editor: Do we have to redefine lameness in the era of quantitative gait analysis. Equine Vet J 2018; 50:415-417. [PMID: 29633362 DOI: 10.1111/evj.12820] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- S Adair
- University of Tennessee, USA
| | - M Baus
- Gran Prix Equine, Connecticut, USA
| | | | - R Bell
- Park Equine Hospital, Kentucky, USA
| | | | | | - F Cardenas
- 3H Equine Hospital and Mobile Veterinary Services, North Carolina, USA
| | - T Casey
- Fourways Equine Clinic, South Africa
| | | | - W Davis
- Palm Beach Equine Clinic, Florida, USA
| | | | - R Farr
- Farr and Pursey Equine Veterinary Services, Hertfordshire, UK
| | - T Fischer
- Chino Valley Equine Hospital, California, USA
| | | | - T Ford
- Ford Veterinary Surgery Center, California, USA
| | | | | | - M Hoge
- Murrieta Equine, California, USA
| | | | - G Hunter
- Ardene House Veterinary Practice, Aberdeen, UK
| | - J Joyce
- Total Equine Veterinary Associates, Virginia, USA
| | - A Kaneps
- Kaneps Equine Sports Medicine and Surgery, Massachusetts, USA
| | | | | | | | | | | | - P Radue
- Damascus Equine Associates, Maryland, USA
| | - R Redding
- North Carolina State University, USA
| | | | - M Rick
- Alamo Pintado Equine Medical Centre, California, USA
| | | | | | | | | | | | - R Thaler
- Metamora Equine PC, Michigan, USA
| | | | | |
Collapse
|
40
|
Möller J, Reiss I, Schaible T, Kohl M, Göpel W, Fischer T, Nitsche E, Krüger S. Oxygenation and Lung Morphology in a Rabbit Pediatric ARDS- Model under High Peak Pressure Ventilation plus Nitric Oxide and Surfactant Compared with Veno-venous ECMO. Int J Artif Organs 2018. [DOI: 10.1177/039139889902201108] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The aim of the study is to investigate which of two treatment options of saline lavage induced ARDS in rabbits is better in terms of oxygenation and prevention of barotrauma: combined high peak pressure ventilation with surfactant administration and inhaled nitric oxide or veno-venous ECMO combined with low peak inspiratory pressure ventilation. Materials and Methods After saline lavage (10 cc/kg repeated as long as foamy retrieval was observed) two combined therapeutic strategies were examined: ventilation with high inspiratory pressures (35 cm H2O) with additional exogenous surfactant administration (100 mg/kg) and inhaled nitric oxide (10 PPM) (n=5, group 1) and low inspiratory pressure (20 cm H2O) ventilation under veno-venous ECMO support (n=5, group 2). The FiO2 was maintained at 1.0 in both groups. The paO2/FiO2 ratio was calculated in 30 minute intervals for 4 hours. After that the animals were sacrificed and the lungs examined macro- and microscopically. Aeration was described in a semiquantitative method using the alveolar expansion index. Oxygenation in group 1 was significantly better than in group 2, it increased significantly after surfactant but not after additional nitric oxide administration. However, the lungs in group 1 showed severe signs of baro/ergotrauma (Hyaline membranes, air leaks, infiltration of polymorphonuclear (PMN) granulocytes and macrophages, break down of alveolar capillary membranes) after 4 hrs of combined therapy, whereas the lungs in group 2 appeared normal. Adding surfactant and NO to a high tidal volume ventilation improved oxygenation, but did not prevent baro/ergotrauma. Ventilation with low inspiratory pressures combined with ECMO caused little baro/ergotrauma but adequate oxygenation could not be achieved, probably due to anatomical features of the rabbit which do not allow appropriate blood flow within the ECMO-circuit.
Collapse
Affiliation(s)
- J.C. Möller
- Departments of Pediatrics and Anaesthesiology, Medical University of Lübeck, Lübeck - Germany
| | - I. Reiss
- Departments of Pediatrics and Anaesthesiology, Medical University of Lübeck, Lübeck - Germany
| | - T.F. Schaible
- Departments of Pediatrics and Anaesthesiology, Medical University of Lübeck, Lübeck - Germany
| | - M. Kohl
- Departments of Pediatrics and Anaesthesiology, Medical University of Lübeck, Lübeck - Germany
| | - W. Göpel
- Departments of Pediatrics and Anaesthesiology, Medical University of Lübeck, Lübeck - Germany
| | - T. Fischer
- Departments of Pediatrics and Anaesthesiology, Medical University of Lübeck, Lübeck - Germany
| | - E.M. Nitsche
- Departments of Pediatrics and Anaesthesiology, Medical University of Lübeck, Lübeck - Germany
| | - S. Krüger
- Institute of Pathology, Medical University of Lübeck, Lübeck - Germany
| |
Collapse
|
41
|
Fischer T, Böttcher B, Mraheel S, Scharl A, Gabruk-Szostak B, Scheidhauer K, Göhring UJ, Meller-Rehbein B, Shukla SK, Schicha H, Schomäcker K. Die Kinetik von rezeptorvermittelter Radiotoxizität des 16α-[125I]-Iodöstradiol-3,17ß. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1632313] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Zusammenfassung
Ziel: Es wurden radiozytotoxische Effekte von 16α-[125l]-lodöstradi- ol-3,17ß ü
125
I]E) an MCF-7-Mammakarzinom-Zellen in Abhängigkeit von der Inkubationszeit in dem Zeitraum zwischen 1 und 24 h untersucht. Methoden: Der Rezeptorstatus der Zellen wurde durch immunhisto- chemische Färbung bestimmt. Die Akkumulation von [125|]E wurde in Gegenwart und Abwesenheit von nichtradioaktivem Östradiol sowie [127I]E und in Östrogenrezeptor (ER)-negativen im Vergleich zu ER-positiven Zellen getestet. Die Ermittlung der subzellulären Verteilung erfolgte in 0,25 M Saccharose durch Ultrazentrifugation. Die Radiozytotoxizität wurde unter den verschiedenen Versuchsbedingungen durch Standard- Kolonie-Assays nach Inkubation mit [125I]E (1.85 kBq/ml-55.5 kBq/ml) für 1, 2, 4, 8, 12 und 24 h ermittelt. Ergebnisse: Eine deutliche Zytotoxizität wurde nur bei Inkubation ER-positiver Zellen mit [125I]E gefunden. Das Maximum lag bei einer Reduktion der Überlebensfraktion auf 20-25% bei Radioaktivitätskonzentrationen im Inkubationsmedium von >37 kBq/ml. Diese maximalen Effekte wurden nach Inkubationszeiten von 8 h gefunden. Eine Verlängerung der Inkubationszeit führte zu keiner weiteren Verstärkung der Toxizität. Schlußfolgerungen: Die Ergebnisse zeigen, daß die Radioaktivität an die Östrogenrezeptoren gebunden wurde. Infolge ihrer Kernlokalisation haben Radioöstrogene, die sehr niederenergetische Elektronen (Auger-Elektronen) emittieren, therapeutische Relevanz durch ER-vermittelte Entfaltung zellinaktivierender, ionisierender Strahlung ohne Beeinflussung benachbarter Zellen. Allerdings sollte anstelle von 125l das kürzerlebige 123l zur Markierung zum Einsatz kommen, da die entscheidenden Strahleneffekte innerhalb von 8 h erfolgen.
Collapse
|
42
|
Wellner U, Scheidhauer K, Gabruk-Szostak B, Fischer T, Steinbach J, Füchtner F, Schicha H, Schomäcker K. Zusammenhänge zwischen Eigenschaften von 131I-Therapiekapseln und der Radioiodkinetik. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1629804] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Zusammenfassung
Ziel: Es sollte das Auftreten nichtreproduzierbarer Meßwerte bei Radioiodtest und Radioiodkinetik unter 131l-Therapie geklärt werden. Methoden: Der lodgehalt der Kapseln wurde kolonmetrisch und mit der Aktivierungsanalyse bestimmt. Die Messung der radiochemischen Reinheit erfolgte mittels HPLC und Elektrophorese. Das Löseverhalten der Kapseln wurde unter unterschiedlichen Bedingungen überprüft. Ergebnisse: Der lodgehalt der Kapseln schwankte zwischen 0,8 und ca. 100 μg/Kapsel. Die radiochemische Reinheit der Kapseln differierte ebenfalls (75%-99,5%). Hauptverunreinigung war lodat. Das Löseverhalten war ebenfalls unterschiedlich. Schlußfolgerung: Zusätzliches nichtradioaktives lod in den Therapiekapseln könnte eine Ursache verminderter Radioiodaufnahme unter Therapie sein.
Collapse
|
43
|
Gaidouk MI, Rumyantseva VD, Fischer T, Lohr H, Salditt S, Liebenhoff S, Schicha H, Schomäcker K. Synthese tumoraffiner Yb-169- und Y-90-Porphyrin-Komplexe und tierexperimentelle Untersuchung verschiedener Yb-169-Porphyrine. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1632222] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
ZusammenfassungZiel: Es wurde untersucht, ob eine Einführung radioaktiver Isotope von Yb und Y in ausgewählte Porphyrine möglich ist. Außerdem sollten erste Daten zur Bioverteilung von radioaktiven Yb-169-Porphyrin-Komplexen gewonnen werden. Methoden: Die Synthesen der Metall-Porphyrin-Komplexe erfolgten mit geträgerten Radiometallen. Erste Tierversuche wurden an Mammakarzinom-tragenden Mäusen durchgeführt. Die Organe wurden 5 und 24 h nach i.v.-lnjektion im Bohrlochdetektor gemessen. Ergebnisse: Es konnten vier Yb-169-Porphyrin-Komplexe und Y-90-Porphyrin-Komplexe in nicht trägerfreier Form synthetisiert werden. Dies wurde anhand der Absorptionsspektren sowie mittels DC und HPLC bewiesen. Je nach Komplex lagen die Tumor/Untergrund-Verhältnisse im Durchschnitt zwischen 2 und 20. Schlußfolgerung: Die synthetisierten radioaktiven Metall-Porphyrin-Komplexe zeigen eine deutliche Tumoraffinität, die bei weiterer Verbesserung der Synthese (Ziel: Trägerreduzierung, andere Radionuklide) eine Tumorszintigraphie und vielleicht -therapie ermöglichen könnte.
Collapse
|
44
|
Börner SM, Fischer T, Hansen H, Schnell R, Zimmermanns B, Tawadros S, Engert A, Staak O, Pogge von Strandmann E, Kobe C, Schicha H, Schomäcker K, Dietlein M. Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Nuklearmedizin 2018; 49:97-105. [DOI: 10.3413/nukmed-0258] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2009] [Accepted: 01/22/2010] [Indexed: 11/20/2022]
Abstract
Summary
Objectives: Comparison of the binding affinity to a CD30-positive Hodgkin lymphoma (HL) cell line and biodistribution in HL bearing mice of new anti-CD30 radioimmunoconjugates (RICs) of varying structure and labelling nuclides. Methods: The antibodies Ki-4 and 5F11 were radioiodinated by the chloramine T method or labelled with 111In via p-NCSBenzyl- DOTA. In addition, the Ki-4-dimer was investigated in the iodinated form. The RICs were analyzed for retained immunoreactivity by immunochromatography. In-vitro binding studies were performed on CD30-positive L540 cell lines. For in-vivo biodistribution studies, SCID mice bearing human HL xenografts were injected with the various radioimmunoconjugates. After 24 h, activities in the organs and tumour were measured for all 5 RICs. Tumour-free animals were studied in the same way with 131I- Ki-4 24 h p. i. The three RICs with the highest tumour/background ratios 24 h p.i. (131I-Ki-4, 131I–5F11, 111In-bz- DOTA-Ki-4) were analysed further at 48 h and 72 h. Results: All the RICs were successfully labelled with high specific activities (28–47 TBq/ mmol) and sufficient radiochemical yields (> 80%). Scatchard plot analysis proved high tumour affinity (KD = 20–220 nmol/l). In-vivo tumour accumulation in % of injected dose per g tissue (%ID/g) lay between 2.6 (131I-5F11) and 12.3 % ID/g (131I-Ki-4) with permanently high background in blood. Tumour/blood-ratios of all RICs were below one at all time points. Conclusions: In-vitro tumour cell affinities of all RICs were promising. However, in-vivo biokinetics tested in the mouse model did not meet expectations. This highlights the importance of developing and testing further new anti-CD30 conjugates.
Collapse
|
45
|
Dietlein M, Schnell R, Pinkert J, Eschner W, Zimmermanns B, Fischer T, Engert A, Schicha H, Schomäcker K. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625104] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
90Y-ibritumomab tiuxetan (Zevalin®) is currently approved for radioimmunotherapy of patients with relapsed or refractory follicular non-Hodgkin’s lymphoma pretreated with rituximab. Future directions are the combined use of 90Y-ibritumomab tiuxetan as part of the initial treatment and as first-line multi-agent therapy of relapsed disease. Current studies investigate patients with other than follicular indolent histologies, e. g. diffuse large cell lymphoma. Labelling of 90Y ibritumomab tiuxetan is a safe procedure, the radiochemical purity is not disturbed by a higher room temperature or by metallic impurity. Quality control is recommended by thin layer chromatography (TLC), strips >15 cm are favourable. TLC cannot distinguish between the correctly radiolabelled antibodies and radiocolloid impurity. If necessary, additional HPLC should be performed. Radiocolloid impurities are absorbed to the solid phase and do not reach the eluate. If the radiochemical purity test is insufficient (<95%), the additional cleaning using EconoPac 10 DG columns (Biorad, Hercules, CA, USA) is a reliable procedure to reduce the percentage of free radionuclide. However, this procedure is not part of the approval.
Collapse
|
46
|
Schomäcker K, Fischer T, Eschner W, Gaidouk M, Schicha H. Exhalation of 1-131 after radioiodine therapy: time dependence and chemical form. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1623987] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Aim: The change of both amount and chemical forms of radioiodine exhaled in the air of rooms with patients on the therapy ward should be investigated depending on radioactivity applied, time after application, and kind of thyroid disease. Methods: The air of ward-rooms of 62 patients with thyroid carcinoma, Graves’ Disease, and autonomy which received different therapy doses, was investigated with an portable constant air flow sampler. Different chemical iodine species (organic, elemental, aerosol bound) were collected during 8 hr in various filters until 3 days after application of the radioiodine capsule, according to their chemical form. The radioactivity in the filters was measured with a well counter on defined time points after application. Results: The radioactivity exhaled was between 0,008 and 0,03% related to activity of radioiodine applied. The percentage of radioiodine exhaled related to the activity applied, differed significantly depending on disease and changed as follows: Grave’s Disease > autonomy > carcinoma. The exhalation of radioiodine became stronger with increasing applied activities and showed an exponential decrease with time. The most part of radioiodine was present in organic bound form. This organic portion decreased with time in favour of the other iodine species. Conclusion: The degree of accumulation of radioiodine orally applied within thyroid seems to be in direct proportion to the extend of its exhalation. Further measurements directly in the breathing air of RIT-patients are necessary, in order to clarify the relationship between degree of thyroid uptake and quantity as well as chemical form of radioiodine exhaled.
Collapse
|
47
|
Abstract
BACKGROUND Social media presents an important means for social interaction, especially among adolescents, with Instagram being the most popular platform in this age-group. Pictures and communication about non-suicidal self-injury (NSSI) can frequently be found on the internet. METHODS During 4 weeks in April 2016, n = 2826 (from n = 1154 accounts) pictures which directly depicted wounds on Instagram were investigated. Those pictures, associated comments, and user accounts were independently rated for content. Associations between characteristics of pictures and comments as well as weekly and daily trends of posting behavior were analyzed. RESULTS Most commonly, pictures depicted wounds caused by cutting on arms or legs and were rated as mild or moderate injuries. Pictures with increasing wound grades and those depicting multiple methods of NSSI generated elevated amounts of comments. While most comments were neutral or empathic with some offering help, few comments were hostile. Pictures were mainly posted in the evening hours, with a small peak in the early morning. While there was a slight peak of pictures being posted on Sundays, postings were rather evenly spread across the week. CONCLUSIONS Pictures of NSSI are frequently posted on Instagram. Social reinforcement might play a role in the posting of more severe NSSI pictures. Social media platforms need to take appropriate measures for preventing online social contagion.
Collapse
Affiliation(s)
- R C Brown
- Department for Child and Adolescent Psychiatry and Psychotherapy,University Hospital Ulm,Ulm,Germany
| | - T Fischer
- Freelancing data journalist,Berlin,Germany
| | | | - F Keller
- Department for Child and Adolescent Psychiatry and Psychotherapy,University Hospital Ulm,Ulm,Germany
| | - R Young
- MRC Social and Public Health Sciences Unit,University of Glasgow,Glasgow,Scotland
| | - P L Plener
- Department for Child and Adolescent Psychiatry and Psychotherapy,University Hospital Ulm,Ulm,Germany
| |
Collapse
|
48
|
Konstantinow A, Fischer T, Zink A. Neck rejuvenation by direct anterior medial cervicoplasty: the modified zigzag-plasty according to Tschopp. J Eur Acad Dermatol Venereol 2017; 32:805-811. [PMID: 29283463 DOI: 10.1111/jdv.14776] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2017] [Accepted: 11/27/2017] [Indexed: 11/29/2022]
Abstract
BACKGROUND Conventional cervicofacial rhytidectomy has become the standard treatment of skin excess of the ageing neck. However, some patients want to avoid an extensive surgical procedure, especially if the anterior neck is the predominant problem zone. OBJECTIVE To report on the efficacy and safety of a zigzag-shaped skin excision combined with platysma plication. METHODS AND MATERIALS We present a retrospective case review series of six female patients. Skin excess was marked preoperatively using the skin pinching technique, then transferred to a zigzag-shaped area and finally excised using the method according to Tschopp, which is described. Patients were followed up for at least 1 year. RESULTS All patients (age: 55-82 years, median: 65 years) were very satisfied with the results. On an overall patient satisfaction scale of 1-10 (1 being the best), the scars were graded on average 1.85 (median: 2) 1 year after surgery. No scar hypertrophy, functional impairment, nerve damage or other serious complications were observed. CONCLUSION In selected patients, the direct anterior zigzag-shaped excision poses an effective, safe and easy surgical option for both skin excess and fat excess and platysma banding. The technique is easily reproducible, with low morbidity and high patient satisfaction.
Collapse
Affiliation(s)
- A Konstantinow
- Department of Dermatology and Allergology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
| | - T Fischer
- Department of Dermatology and Allergology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
| | - A Zink
- Department of Dermatology and Allergology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany
| |
Collapse
|
49
|
Brächer T, Fabre M, Meyer T, Fischer T, Auffret S, Boulle O, Ebels U, Pirro P, Gaudin G. Detection of Short-Waved Spin Waves in Individual Microscopic Spin-Wave Waveguides Using the Inverse Spin Hall Effect. Nano Lett 2017; 17:7234-7241. [PMID: 29148808 DOI: 10.1021/acs.nanolett.7b02458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
The miniaturization of complementary metal-oxide-semiconductor (CMOS) devices becomes increasingly difficult due to fundamental limitations and the increase of leakage currents. Large research efforts are devoted to find alternative concepts that allow for a larger data-density and lower power consumption than conventional semiconductor approaches. Spin waves have been identified as a potential technology that can complement and outperform CMOS in complex logic applications, profiting from the fact that these waves enable wave computing on the nanoscale. The practical application of spin waves, however, requires the demonstration of scalable, CMOS compatible spin-wave detection schemes in material systems compatible with standard spintronics as well as semiconductor circuitry. Here, we report on the wave-vector independent detection of short-waved spin waves with wavelengths down to 150 nm by the inverse spin Hall effect in spin-wave waveguides made from ultrathin Ta/Co8Fe72B20/MgO. These findings open up the path for miniaturized scalable interconnects between spin waves and CMOS and the use of ultrathin films made from standard spintronic materials in magnonics.
Collapse
Affiliation(s)
- T Brächer
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - M Fabre
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - T Meyer
- Fachbereich Physik and Landesforschungszentrum OPTIMAS, Technische Universität Kaiserslautern , 67663 Kaiserslautern, Germany
| | - T Fischer
- Fachbereich Physik and Landesforschungszentrum OPTIMAS, Technische Universität Kaiserslautern , 67663 Kaiserslautern, Germany
- Graduate School Materials Science in Mainz , Gottlieb-Daimler-Strasse 47, D-67663 Kaiserslautern, Germany
| | - S Auffret
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - O Boulle
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - U Ebels
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| | - P Pirro
- Fachbereich Physik and Landesforschungszentrum OPTIMAS, Technische Universität Kaiserslautern , 67663 Kaiserslautern, Germany
| | - G Gaudin
- University Grenoble Alpes, CEA, CNRS, Grenoble INP, INAC, SPINTEC , F-38000 Grenoble, France
| |
Collapse
|
50
|
Nimmagadda SC, Frey S, Edelmann B, Hellmich C, Zaitseva L, König GM, Kostenis E, Bowles KM, Fischer T. Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia. Leukemia 2017; 32:846-849. [PMID: 29109446 PMCID: PMC5843904 DOI: 10.1038/leu.2017.324] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
- S C Nimmagadda
- Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany
| | - S Frey
- Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany
| | - B Edelmann
- Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany
| | - C Hellmich
- Department of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, Norwich, UK
| | - L Zaitseva
- Department of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, Norwich, UK
| | - G M König
- Institute of Pharmaceutical Biology, University of Bonn, Bonn, Germany
| | - E Kostenis
- Institute of Pharmaceutical Biology, University of Bonn, Bonn, Germany
| | - K M Bowles
- Department of Molecular Haematology, Norwich Medical School, The University of East Anglia, Norwich Research Park, Norwich, UK.,Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Colney Lane, Norwich, UK
| | - T Fischer
- Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University, Magdeburg, Germany
| |
Collapse
|